[{"article": "They then transplanted them into mice with a disease akin to type 1 diabetes.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "News stories often don\u2019t address the novelty of a treatment or research finding. But this story actually uses the word \u201cnovel,\u201d which sort of puts a spotlight on the category for us. The story quotes one of the study\u2019s funders calling the protective cell bubbles studied in the research \u201cnovel materials.\u201d We think the story actually does establish their novelty with enough context and caveats.", "answer": 1}, {"article": "Agatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\nOne large federally funded study found the coronary calcium score a better predictor of coronary events like a heart attack than the traditional Framingham Risk Score, which considers age, cigarette smoking, blood pressure, total cholesterol and HDL, the \"good\" cholesterol.\nCardiologists now generally use the calcium scan only for patients considered at intermediate risk for heart disease, determined by traditional measures such as cholesterol, blood pressure, lifestyle and family history.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Coronary calcium scoring has been a hot topic in heart disease prevention for well over a decade. Does it still qualify for the \u201crelatively new\u201d description used in this story? Certainly there is an evolving scientific discussion about which individuals are likely to benefit from these tests, but that sort of nuance is largely missing from this story.", "answer": 0}, {"article": "That's a potentially life-saving development.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\n\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nWith this you just slap a little patch on their backs.\u201d\n\nAlthough some volunteers experienced redness and itchiness at the site of the patch, there were no serious side effects.\nIn the skin patch trial, the international team of researchers randomly assigned 221 volunteers, ages 6 to 55, to wear a placebo patch or a patch containing peanut protein at one of three doses: 50 micrograms, 100 micrograms or 250 micrograms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to oral immunotherapy \u2014 a similar approach to desensitization that has been more thoroughly tested than the skin patch \u2014 but as noted above, it does not provide any real discussion of how the two compare. Nor does it explain that the patch has already been tested in a pilot study that didn\u2019t find any benefit for the patch over a placebo. What\u2019s different about the current study that led to a higher success rate? A bit more context was needed to satisfy this criterion.", "answer": 0}, {"article": "But many others are tough calls.\nThe device is approved only for dermatologists and only for use on growths that don't have obvious signs of cancer but still have one or two worrisome traits.\nThe device's handheld attachment, about the size of a blow dryer, emits light that penetrates below the surface of the skin, taking multicolored images that reflect the depth and shape of skin growths.\nThe hope is to find more melanomas sooner.\nThe company plans to bring them next year to just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls the device a \u201cfirst of its kind,\u201d but it also explains that it is only approved for use in a subset of patients and that much more work needs to be done.", "answer": 1}, {"article": "MORE: You Asked: Should I Take Probiotics?\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\nThe study\u2019s findings need to be confirmed in larger independent trials, and McIntyre says he wouldn\u2019t yet recommend taking a probiotic for symptoms associated with mental disorders like depression or anxiety.\nWhile their data did not show significant independent changes in anxiety, constipation, diarrhea or pain, people who took the probiotic did report improvements in overall symptoms of IBS and in quality of life.\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of establishing where\u00a0the true novelty of the research lies, which is in the study population used (individuals without IBS and depression or anxiety).", "answer": 1}, {"article": "The findings were to be presented Monday at the annual meeting of the American Urological Association (AUA), in Washington, D.C. Research presented at medical meetings should be viewed as preliminary until it has been published in a peer-reviewed medical journal.\nChildren in the study were aged 5 to 18, and were followed for just under one year after their surgery, on average.\nExactly how sleep apnea results in bedwetting is not fully understood, but hormonal changes may play a role.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\n\"Children snore because their tonsils and adenoids are enlarged, and they end up getting other behaviors that go along with sleep apnea, including bedwetting,\" she explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Treating sleep apnea surgically for bedwetting is not novel, but this story does not make a clear case for novelty or against it.", "answer": 0}, {"article": "Nov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least stated that \u201cthe new study is the first to establish a direct relationship between fish consumption, brain structure and Alzheimer\u2019s risk\u201d and that \u201cSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer\u2019s disease.\u201d\n ", "answer": 1}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n\u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention or discuss the novelty of the research or the health claims associated with blueberries. The study upon which the story is based references several prior studies of blueberries, or a plant-rich diet, and hypertension.", "answer": 0}, {"article": "Reiman wrote a commentary that accompanies the study in Nature.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\nBut last summer, Biogen began presenting its results with aducanumab at scientific meetings, including the Alzheimer's Association International Conference in July.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what appears to be novel about this drug compared with others that reduce amyloid plaques.\nOne is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut while the story is clear that the new paper is presenting details of research first reported last year, it doesn\u2019t explain why the results are now \u201cremarkable\u201d whereas last year they were considered \u201cdisappointing,\u201d\u00a0\u201cmixed\u201d\u00a0and a \u201csetback.\u201d\nWe\u2019ll rate this a borderline Satisfactory.", "answer": 1}, {"article": "\u201cThere\u2019s been a longstanding fear of skin testing, and it turns off a lot of allergy sufferers from getting help,\u201d said Dr. Mitchell, the author of \u201cAllergy and Asthma Solution\u201d (Marlowe, 2006), which advocates oral immunotherapy, or allergy drops, instead of shots.\nThe lab sends the physician a report with these figures and the patient\u2019s risk of a reaction.\nIf he requests a blood test, the laboratory gets the fee.\n\u201cA lot of academic allergists are very conservative,\u201d he said.\nThe size of the wheal and the diameter of the redness help determine if the patient is allergic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the blood tests were developed in the 1970s but that newer tests have become available more recently.", "answer": 1}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\nTo measure levels of optimism, participants were asked to use a five-point scale to either agree or disagree with six statements, such as, \u201cIn uncertain times, I usually expect the best.\u201d\n\nThe results showed that the most optimistic women \u2013 those in the top 25 percent \u2013 had a nearly 30 percent lower risk of dying from any of the diseases analyzed in the study when compared to the least optimistic participants in the lowest 25 percent.\n\u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n\nShe said her team plans to focus more on the potential impact of optimism on biological functioning in future research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0explains what\u2019s novel here is how the research looks at all-cause mortality vs specific health behaviors and outcomes. This is established with this statement:\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News. \u201cSo in our study we wanted to expand that and look at all-cause mortality\u00a0and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d", "answer": 1}, {"article": "Samit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\nLike other companies, Novartis is seeking to personalize treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn\u2013via the lead researcher\u2013that this trial provides the \u201cmost encouraging\u201d results to date in a study looking at a PI3K inhibitor in breast cancer. That establishes novelty, but we think the story should have sought independent expert viewpoint to provide context on the limitations of the results, which were based on progression-free survival and not overall survival.\nIt does not include the information that one other PI3K inhibitor is currently on the market and used to treat a type of lymphoma.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that cupping therapy is not a new approach, as it was \u201cperformed traditionally in China and other countries.\u201d Even the headline reads, \u201cCenturies-Old Art of Cupping May Bring Some Pain Relief.\u201d", "answer": 1}, {"article": "She had tried everything.\n\"We have two-thirds of all Americans who are overweight or obese, and the costs are nearing $150 billion a year,\" says Christine Ferguson, a health policy professor at George Washington University.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\nYou recall the fen-phen episode where a significant number of people got heart-valve defects,\" says Janet Woodcock, a top FDA official.\nBarbara Troupin of Vivus, the company that is developing Qnexa, says the drug appears to do a lot more than just help people lose weight.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As the caption under the story\u2019s photo explains, \u201cThe FDA hasn\u2019t approved a new weight-loss drug since 1999.\u201d\u00a0 But the story didn\u2019t explain, as a Bloomberg story did, that \u201cQnexa is one of three obesity drugs vying to be the first in 13 years on the market.\u201d\u00a0 We think that was an important angle to include.\nIt also could have explained that Qnexa is a combination of two drugs that are well known to cause weight loss (phentermine, the phen in phen-fen and topiramate an antiseizure drug that has weight loss as a side effect).", "answer": 0}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\nHowever, one patient died of a stroke while convalescing after suffering a heart injury during implantation and another had the pacemaker replaced with a defibrillator.\nThe new pacemaker is about the size of a AAA battery and provides jolts to one chamber of the heart, Reddy said.\nHe expects the pacemaker \"will likely be utilized for some select patients\" after more testing.\nSome are combined with defibrillators, which give the heart a major jolt when needed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Even a quick online search shows that there are other wireless pacing devices in various stages of testing as well, yet the story makes no mention of these.", "answer": 0}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty for this particular association of statins with decreased cancer risk. There have been a number of large meta-analyses and retrospective studies about statins and cancer risk reduction (all showing different findings), and this latest result should have been placed in context within the body of research.\nIt is implied (but not stated) that perhaps the use of 1 million patient records is the largest study searching for the correlation \u2013 but the story does not state it.", "answer": 0}, {"article": "Although approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nAn ultrasound instrument with a vibrating needle is used to break up the cataracts, and a vacuum sucks them out.\nA permanent artificial lens is then implanted to replace the natural lens and provide appropriate vision correction for each patient.\nIt can hinder recovery and cause clouding of the cornea, which is the clear outer layer of the eye.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not exaggerate the novelty of this procedure, which is just starting to be evaluated clinically.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that Erbitux was first used to treat colon cancer, but is now approved to treat head and neck cancer.", "answer": 1}, {"article": "\"At age 11, I developed this condition, called alopecia areata, where I lost my hair,\" says Velasquez-Manoff, a science writer in Berkeley, Calif. \"It started in patches, but eventually I lost it all.\"\nYou see, the worms don't shut down the immune system completely \u2014 just enough so that the immune cells won't attack the worm.\nThe first study to finish was a big one in Europe that looked to see if pig whipworms helped with Crohn's disease.\nIt's unclear why the worms haven't worked in these trials, Loke says.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty by letting us know that studies go back a few years, so it\u2019s not a new concept.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this class of \"self-injectable biologic\" drugs was discussed in the story. ", "answer": 1}, {"article": "Previously, no treatment was available for these patients.\"\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that this is only the second pharmaceutical treatment for HCC proven to affect patient survival, and outlines what the study findings may mean for future research on how regorafenib may be used in treating earlier stages of HCC.", "answer": 1}, {"article": "Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nIn addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Br\u00e9zin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty is somewhat nuanced, but explained well enough: Uveitis is a bag full of symptoms, and the damage involved can span across the entire eye. By measuring how it affected the most frequent symptoms, \u201cthe study\u2019s results broaden the applicability of treatment for patients\u201d and possibly help lead to longer-term solutions for uveitis.", "answer": 1}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nFor more information, please contact: \n\nJoel Winston \n\nPublic Relations Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nj.winston@qmul.ac.uk \n\nTel: +44 (0)20 7882 7943 / +44 (0)7970 096 188\n\n* Research paper: 'Changes in the Frequency of Airway Infections in Smokers who Switched to Vaping: Results of an Online Survey'.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nHowever, the present results provide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\"\nThe results, published in the Journal of Addiction Research & Therapy, show that 66 per cent of respondents reported an improvement in respiratory symptoms, 29 per cent reported no change and 5 per cent reported worsening.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release is not the novelty of e-cigarettes but the novelty of the research. We give it a satisfactory for including this statement which puts the research in context:\n\u201cSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels. Human trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\u201d", "answer": 1}, {"article": "These weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\nThe coronary heart disease patients who stuck with the recommended 150 minutes a week had the lowest risk for heart attack and stroke.\nIt\u2019s the person who wakes up at the crack of dawn on the weekend, puts on shiny spandex and disappears with a mountain bike for hours at a time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish what\u2019s novel, unlike what we saw in our review of The Guardian\u2019s story.", "answer": 0}, {"article": "While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release implies novelty by stating that the research \u201chelps pave the way\u201d for a new treatment option. Deep brain stimulation is used for other brain disorders, so it is obviously not a new device or new surgical approach, and the release makes this clear. However, as an approach to treat Alzheimer\u2019s disease it is novel.", "answer": 1}, {"article": "* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nA1C levels on average decreased to 7.5 percent from a baseline of 8.3 percent in the group on pump therapy, but decreased to just 8.1 percent in the group receiving multiple injections.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nMultiple daily injections remain the most common approach to controlling blood sugar levels.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe novelty of insulin pumps and monitoring sensors was not part of this story.", "answer": 2}, {"article": "Feb. 4, 2016.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\nWe are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n\nAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries.\nTuuli MG, Liu J, Stout MJ, Martin S, Cahill AG, Odibo AO, Colditz GA, Macones GA. A randomized trial comparing skin antiseptic agents at cesarean delivery.\nTuuli and his colleagues also pointed out that the superiority of the chlorhexidine-alcohol combination was consistent whether the C-section was scheduled or unscheduled, whether or not the patient was obese, whether staples or sutures were used to close the wound and whether the patient had chronic medical conditions, including diabetes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explained that other studies have examined skin-prep, but this one was the first to directly compare dual-element preps for C-sections. Here is an excerpt:\n\u201cPast trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone. These studies could not determine whether the worse performance of iodine alone was due to the chlorhexidine, the alcohol or the combination.\u201d", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release explains the significance of the study in supporting initiation of a randomized trial. However, the results are not entirely \u201cnew,\u201d as the release states; they were previously reported at a medical conference in June 2016. Also, we found it interesting that the published study states its results are consistent with three similar trials, including this Canadian study, bolstering the validity of its finding. Those trials are not mentioned in the news release.\nThe idea of using bone marrow transplantation for medical illnesses is not new. During the 1990s bone marrow transplantation following high dose chemotherapy was touted as a cure for breast cancer. \u00a0A randomized clinical trial was begun in the late \u201990s but was discontinued when results from the initial studies were found to\u00a0have been fraudulently reported. (Described in a book called \u201cFalse Hope: Bone Marrow\u00a0Transplantation for Breast Cancer\u201d by Peter D. Jacobson and Richard A.\u00a0Rettig.)", "answer": 0}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\nPrevious research suggests that in a 24-hour period, the average person with type 1 diabetes spends about 10 hours with blood sugar levels too high, and about an hour a day with blood sugar levels too low, according to Aaron Kowalski, assistant vice president for treatment therapies at the Juvenile Diabetes Research Foundation.\nFor the eating-in portion of the randomized study, 12 of the study volunteers were assigned to consume a medium-sized meal (60 grams of carbohydrates) at 7 p.m., and then another half were placed on the artificial pancreas program during the night, while the other half maintained their standard insulin pump therapy.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story, like the study, points out that the connection between statin use and renal protection has only been seen in animals. We think the story makes it clear to readers that what\u2019s new and important here is showing a relationship in humans as well.", "answer": 1}, {"article": "The process of RNA interference involves putting two strands of RNA together to form so-called \"small interfering RNAs\" (siRNAs) and inserting them into cells.\n\"This is something we've been waiting to see,\" he continued.\nThis team, from the California Institute of Technology (CalTech), devised a super-small nanoparticle system that, when injected into the body, would make its way to the tumor, deposit the siRNAs into the tumor cell and leave them to their assigned task.\n\"This is one step away from getting into the actual DNA.\"\n\"They're basically putting an instruction booklet into the cell saying, 'We don't want this protein expressed for now,'\" explained Gregory Adams, co-leader of the developmental therapeutics program at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good job on establishing the novelty of this approach \u2013 and reminding readers that this work lead to a Nobel Prize in 2006 for research in worms \u2013 \"a far cry from humans,\" as the story states. ", "answer": 1}, {"article": "\u2022 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer's, compared with controls.\nAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina.\nWe look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer's, both in identifying and monitoring those who may be affected by the disease.\nThey also provide detailed analyses and several new findings on Alzheimer's pathology in the retina, results of research with donated eyes and brains of 37 deceased patients, 23 with confirmed Alzheimer's disease and 14 controls.\n\u2022 The first report of certain Alzheimer's-related pathologies in the retina, including vascular amyloid pathology.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the novelty of the findings in several areas, noting:\nThe article provides new insights into the disease\u2019s manifestations in the retina and information on the optical imaging system. Here are several highlights:", "answer": 1}, {"article": "Italian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nWhile most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the study as new but fails to indicate whether or not the drug and procedure are new. And as the editorial points out, there are 5 other studies testing this so there is more data out there and it appears to be a bit contradictory.\n", "answer": 0}, {"article": "\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\nFurthermore, at mid-point, 60 percent of the mothers had low depression scores; this percentage rose to 75 percent at end.\nOn average, they spoke about three times.\nThe women who volunteered as peer counselors attended an eight-hour training course and received reference materials about postpartum depression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to previous studies suggesting the value of peer counseling. It\u2019s clear that this is not the first such study.", "answer": 1}, {"article": "For further information, please visit: http://www.\nBethan Hughes, from Wellcome's Innovation team said: \"This innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases.\n\u2022 Link to paper: The following link will go live at the time the embargo lifts: https:/\n\u2022 For embargoed copies of the BRAIN paper and for media enquiries please contact Maggie Stratton: m.stratton@wellcome.ac.uk +44 (0)20 7611 8609/ +44 (0)787 211 2656\n\u2022 For further information about DARC technology please contact Emma Alam: e.alam@uclb.com +44 (0)207 679 9000/ +44 (0)7896 058667\n\nUCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\nProfessor Philip Bloom, Chief Investigator at Western Eye Hospital, part of Imperial College Healthcare NHS Trust, added: \"Treatment is much more successful when it is begun in early stages of the disease, when sight loss is minimal.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to the tool under development as a \u201cpioneering diagnostic.\u201d A researcher is quoted saying, \u201cNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.\u201d\nWe\u2019ll give the release the benefit of the doubt that the test may potentially be novel for glaucoma but not for any neurological disease for which it hasn\u2019t even been tested.", "answer": 1}, {"article": "So why does acupuncture seem to work?\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nRazzini didn't know how much American patients might have to pay for such treatment, but added, \"Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.\"\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the weakest spot for the story. We found\u00a0three other papers that evaluated acupuncture as a means of addressing hot flashes for cancer patients: this one from 2007, one from 2009, and another from 2009. The findings from the studies are not all in agreement (with each other, or with the study being discussed in this story).\nWhat does it tell us that we didn\u2019t already know? Does it build on previous work? Looking at all of the work on this subject, what do we know about this form of treatment? Those are good questions\u2013important questions\u2013and this story doesn\u2019t address them.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news hook here is the FDA approval of this drug combination. We\u2019ve already given the story credit for this above under \u201cAvailability.\u201d And we\u2019d note that just because the FDA approves something, doesn\u2019t mean that it\u2019s novel. There are plenty of \u201cme-too\u201d drugs out there, and this story doesn\u2019t make any attempt to clarify how this new drug combination works differently or better than existing drugs.", "answer": 0}, {"article": "He says coffee can also be addictive and some people may suffer from withdrawal headaches.\nHe adds that when it comes to the link between coffee and head and neck cancer, \"the benefits outweigh the risks and this is just one more piece of that puzzle that supports that.\"\nWhile these results are encouraging, it doesn't mean we should just go out and start drinking lots of coffee, says Mia Hashibe, lead researcher and an assistant professor in the department of family and preventive medicine at the University of Utah.\nBut coffee contains over 1,000 different chemical compounds, including cancer-fighting antioxidants, and it\u2019s those antioxidants that may provide a \u201cplausible explanation\u201d for reducing the cancer risk, says Hensrud.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least briefly mentions other coffee research: \"Other recent studies suggest coffee may have beneficial effects in other diseases like dementia, diabetes, liver and Parkinson\u2019s disease. However, coffee alone may not be the answer according to some experts.\"", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\n\"Psoriasis and psoriatic arthritis are chronic inflammatory conditions that can be quite uncomfortable and often painful for patients, so any treatment that might reduce symptoms may improve quality of life,\" says lead study author Soumya Reddy, MD, an assistant professor of medicine in the division of rheumatology at NYU Langone, and co-director of NYU Langone's Psoriatic Arthritis Center.\n\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "One could easily come away from this release thinking that these researchers are the first to report psoriasis symptom reduction in those undergoing bariatric surgery (with resultant weight loss). However, such findings have been reported before, and the release does not acknowledge this.", "answer": 0}, {"article": "July 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nThere are two forms of AMD, a wet form and a dry form.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\nIt damages the center of the retina, or macula, and results in a loss of vision in the center of the visual field.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach and the void it would fill in treatment is explained. ", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the procedure has been in use for decades. What could have used more exploration\u2013from independent sources\u2013is whether it\u2019s overused.", "answer": 1}, {"article": "The current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nTwo of these drugs, Vertex Pharmaceutical's telaprevir and Merck's boceprevir, are in the final stages of study and may make it to the market as early as next year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there are many other drugs being developed to treat hepatitis C. It explained that a potentially novel advantage of the new compound is that it seems to be effective against all genotypes.", "answer": 1}, {"article": "\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nOne patient has gone without insulin injections for 3.5 years.\nThe experimental treatment is called autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT).\nThe blood stem cells are then removed from the body and frozen.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledged that other stem cell studies showed promising results for Type 1 diabetes.", "answer": 1}, {"article": "What's lacking are clinical studies.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\nFamily-centered cesareans are a relatively new idea in the U.S., and many doctors and hospitals have no experience with them.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece presented the family-centered cesarean as a \u201crelatively new idea in the US\u201d and mentioned that it has been \u201cslow to catch on.\u201d But media outlets have been writing about it since London-based professor NM Fisk wrote about the idea in 2008 in the journal BJOG. Brigham and Women\u2019s Hospital in Boston also released a press report in June 2013.\nAlthough the phrase \u201crelatively new\u201d is vague, we think it\u2019s enough for a satisfactory rating.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that both low-carb and low-fat diets are proven to produce weight loss. However, it suggests that we should be surprised that a low-carbohydrate diet could produce such beneficial effects on blood pressure.\u00a0In fact, this effect was well-documented in another comparison\u00a0of weight loss diets\u00a0published in JAMA in 2007.", "answer": 0}, {"article": "\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\n\"There\u2019s a huge economic cost to divorce, and this is often cited as one of the main reasons for a divorce,\u2019\u2019 Goldstein said.\n\"To the extent that the drug may act as an incentive to bring the subject up, that will be a good opportunity,\u2019\u2019 he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story is accurate in stating that\u00a0if approved, flibanserin would be the first drug of its kind for pre-menopausal women.\u00a0 It does acknowledge that\u00a0other efforts to produce a similar drug have been unsuccessful. ", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nThe findings are the result of a combination of experimental studies, computational studies and human studies, Rimer said.\nThey often recommend taking citrate (CA), in the form of potassium citrate, a supplement that can slow crystal growth, but some people are unable to tolerate the side effects.\nMpourmpakis and Taylor applied density functional theory (DFT) - a highly accurate computational method used to study the structure and properties of materials - to address how HCA and CA bind to calcium and to calcium oxalate crystals.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There do not appear to be any other studies available on www.PubMed.gov that look at hydroxycitrate as a potential kidney stone treatment.", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nThe authors reported no serious side effects associated with selenium during the study.\nTheir results are published in Annals of Internal Medicine.\nThe finding \u201cis not generalizable to other patients,\u201d he said.\nGuallar and his colleagues wanted to look specifically at the link between selenium and cholesterol.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges previous research that had linked high selenium with higher cholesterol levels.", "answer": 1}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\nI see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that medical device makers have been working for years to develop a so-called artificial pancreas.\u00a0While this is perhaps enough to satisfy the criterion, the story\u00a0could have\u00a0mentioned\u00a0that some of the most important features that an \"artificial pancreas\" might provide\u00a0can already be found on commercially available products. A Medtronic Insulin pump can suspend insulin delivery when\u00a0it\u00a0gets a low blood glucose reading from the continuous glucose monitor to prevent hypoglycemia. This pump is not available in the U.S. because it doesn\u2019t have regulatory approval\u2013something that is also likely to take\u00a0a long time for an \"artifical\u00a0pancreas.\" \u00a0\u00a0\u00a0", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We readily admit that we\u2019re holding the story to a high standard here, but we do so unapologetically. In the context of a news story, any time something is not specifically labeled as \u201cnot new,\u201d readers will likely infer that it is new.\u00a0However, this technology has been around for quite some time, and the story doesn\u2019t really establish that fact. The story does note that the study funded by a device manufacturer dates back to 2005. But it wasn\u2019t new even then. For example, California\u2019s Department of Health Services issued an updated(!) fact sheet on the health hazards of these devices in January of 1998. Establishing that back story would\u2019ve clued readers in to the fact that we\u2019ve seen this movie before.", "answer": 0}, {"article": "Funding came from the National Institutes of Health and the American Heart Association.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions early research by cardiologists from the same institution documenting stiff left ventricles in middle-aged people who don\u2019t exercise. It\u2019s mentioned that this study is unique in asking the question: can exercise restore heart elasticity in previously sedentary, middle-aged people?\nWe\u2019ll rate this satisfactory. But really, this is just one of innumerable studies that show exercise is beneficial. It might be measuring the benefit in a novel way but, in the end, it is just suggesting that exercise is good.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Physicians have treated Parkinson\u2019s patients with the drugs pergolide and cabergoline for a long time. The news article accurately represents their controversial history, though it neglects to note that other medicines in this drug class are avaliable that do not appear to cause heart valve disease.", "answer": 1}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nIt might be that Canadian doctors were not sufficiently skilled.\nIt looks for blood in the stool, which can arise from colon cancer.\nAnd they should do a high volume of screening.\nThey should take at least eight minutes to withdraw an endoscope from the colon.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly colonoscopy is not a new idea.", "answer": 1}, {"article": "About Camurus\n\nCamurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\nCAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\nIn September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead candidate, Probuphine\u00ae, a six-month buprenorphine implant for treatment of opioid addiction.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests the product under development is \u201cnovel\u201d and that it \u201chas the potential to alter the current treatment paradigm for opioid dependence.\u201d We aren\u2019t really told what is novel about the formula, though. A weekly or monthly administered opiate antagonist would be a new addition to the treatment options but it is not really novel.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re only told that this is a new device, newly approved by the FDA. \u00a0But its unique place in the treatment of this brain tumor type is not clearly defined. In reality, the use of weak electrical fields to interrupt cancer cell growth has been known for some time. But we\u2019re not given any of that context.", "answer": 0}, {"article": "Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\n\u201cThis is how things are in bed, covered under duvets or a blanket.\u201d\n\nFor one night of the study, 17 volunteers slept with an open window or internal door.\n\u201cWe spend nearly a third of our life in the bedroom environment, but the air quality in our sleeping environment is often overlooked,\u201d said study author Dr. Asit Mishra of Eindhoven University of Technology.\n\u201cSleep quality is affected by many factors, such as health and emotional states, bedding conditions and different environmental conditions, including noise levels and temperature,\u201d said Dr. Nuno Canha of the University of Lisbon in Portugal.\n\u201cImagine this - you are in a confined space and have limited ability to adjust the situation (since you are asleep) while you are possibly surrounded by pollutants,\u201d he told Reuters Health by phone.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish what makes this research novel. It\u2019s fairly well-known that indoor air quality can be poor, and that ventilation can help circulate the air.", "answer": 0}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\n\"These include reducing inflammatory responses, increasing micronutrients, improving vitamin and mineral imbalances, changing lipid profiles by using olive oils as the main source of dietary fats, maintaining weight and potentially reducing obesity, improving polyphenols in the blood, improving cellular energy metabolism and maybe changing the gut micro-biota, although this has not been examined to a larger extent yet.\"\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\n\"I would therefore recommend people to try to adhere or switch to a MedDiet, even at an older age,\" Hardman added.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Studies of this diet are numerous. Although this meta-analysis may be unique in its analytical characteristics, the text makes no claim for novelty.\nThe release includes quotes which make the study sound like new information, when it really isn\u2019t. For example:\n\u201cThe most surprising result was that the positive effects were found in countries around the whole world. So regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers.\u201d", "answer": 0}, {"article": "That aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Spinal cord stimulation appears to have been around for years, though the marketing of these devices appears to be on the upswing. One concern: The piece refers to her getting a \u201cnext generation stimulator. This implies that there is a prior generation one, and we\u2019re not sure what the difference is.", "answer": 1}, {"article": "In clinical trials, a plant-based diet lowers total cholesterol by 12.5 mg/dL.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\n\u2022 In clinical trials, a plant-based vegetarian diet lowers LDL cholesterol by 12.2 mg/dL and reduces HDL cholesterol by 3.4 mg/dL, compared to control groups following an omnivorous, low-fat, calorie-restricted, or a conventional diabetes diet.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\nThe study authors--Yoko Yokoyama, Ph.D., M.P.H., Susan Levin, M.S., R.D., C.S.S.D., and Neal Barnard, M.D., F.A.C.C.--reviewed 30 observational studies and 19 clinical trials, which met their inclusion criteria.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Is it novel to show that vegetarian diets are associated with lower cholesterol? Other studies have examined the relationship between vegetarian diets and plasma lipid levels, and comparing them with omnivorous diets, found there was no difference in high density lipoprotein cholesterol (HDL-c).\nWe wondered if there was some other aspect of the study that made it novel. The release notes that the study goal was to examine the association between a vegetarian diet and plasma lipid levels \u201cthroughout the lifespan.\u201d According to the published study, this was the first meta-analysis to do so on a \u201clong-term\u201d basis. However, to be included in the analysis, clinical trials and observational studies only had to be 4 weeks of duration \u2014 hardly \u201clong-term.\u201d\n\u00a0", "answer": 0}, {"article": "\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\nThen they injected the cells into rats that had heart attacks and tried to manipulate the cells with a toy magnet.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\nThe U.S. National Library of Medicine has more on heart disease.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No context given on other research to enhance cardiac stem cell interventions. ", "answer": 0}, {"article": "That year, Dr. Mack, who was then the president of The Society of Thoracic Surgeons, and other leaders met with the F.D.A.\nIt was written into the Medicare coverage decision, a first for a medical device.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\n\u201cThis technology is expensive and high risk,\u201d Dr. Mack said.\n\u201cIf we treat five patients, we would save a life in the first year,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is described nicely \u2014 the article goes into depth on the history of the device.", "answer": 1}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes what the study set out to do \u2014 measure changes in weight and in subfascial and intramuscular fat and how these change can impact metabolism. But the study isn\u2019t novel. Numerous studies have been conducted on the effects vegetarian diets have on different types of body fat as well as weight and metabolism.", "answer": 0}, {"article": "Standard guidelines for stroke treatment currently recommend clot removal only within six hours of stroke onset.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\nThere was no difference in mortality or other safety end-points between the two groups.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release might have noted that previous research had suggested that some extension of the six-hour timetable for optimal clot removal was possible, even for medical therapy. But overall, the release makes clear why and how this trial was novel.", "answer": 1}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good historical context, explaining that \u201cInterestingly, the drug is not new \u2014 it\u2019s just taken a long and circuitous route to approval.\u201d", "answer": 1}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The column did a solid job summarizing the current status of research in this field.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes how the new tests wed radioactive tracing materials with an amino acid (in the case\u00a0of the prostate cancer) and other molecules, and sufficiently explains how the new tests differ from current nuclear images.", "answer": 1}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\n\"The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,\" says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths.\nIn a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin -- the active compound in hallucinogenic \"magic mushrooms.\"\nThe researchers assessed each participant's mood, attitude about life, behaviors and spirituality with questionnaires and structured interviews before the first session, seven hours after taking the psilocybin, five weeks after each session and six months after the second session.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release places the work in the context of previous research from Johns Hopkins, which is enough \u2014 barely \u2014 to earn it a satisfactory rating here. What we would really like to see is how this work compares to previous research done specifically on the use of psilocybin to treat anxiety in cancer patients \u2014 such as this 2007 study, this one from 2011, or this one from 2013. We don\u2019t necessarily expect an exhaustive comparison, but there needs to be at least some recognition that other work has been done in this field over the past 10 years.", "answer": 1}, {"article": "Yet the study suggests the opposite has happened.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\n\u201cEven if we didn\u2019t change opioid prescribing at all, the data here suggest that we could cut overdoses dramatically just [by] getting prescribers to not put people on a benzodiazepine at the same time,\u201d Humphreys said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says researchers \u201cjust uncovered\u201d the danger of tandem opiod/benzodiazepine use and quotes a researcher saying the study \u201creveals an underappreciated policy lever for reducing drug overdoses: Making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\u201d\nIn fact, this has been the radar of the medical community for awhile. A 2015 study found veterans using opioids had a higher risk of death from drug overdose if they also used benzodiazepines. And last year two government agencies took action: The U.S. Centers for Disease Control and Prevention amended guidelines to discourage clinicians from prescribing both types of drugs simultaneously, while the FDA advised of the dangers of mixing the drugs and strengthened warning labels and patient medication guides for nearly 400 products.\nInstead, the challenge has been figuring out how to get patients off of this drug combination and recent\u00a0research/care delivery redesign efforts are tackling this issue (but this article doesn\u2019t not get into this at all, nor is this what the research study is about).", "answer": 0}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Patients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a consultation or second opinion.\n\"These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient's individual genetic profile,\" said Dr. Samadi.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The findings reported in the study seem to be newsworthy, and we\u2019ll give credit\u00a0for indicating that \u201cnew research has revealed\u201d and \u201cthis discovery\u201d as\u00a0establishing novelty. There\u2019s also a nod to previous research about prostate cancer genetics.", "answer": 1}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nIt may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While technically a novel result, it\u2019s a minor one. We found a 2014 study in Anesthesia & Analgesia that explored the same question, though in a Chinese population and with greater rigor. That study compared women who chose epidurals to those who chose a \u201cnatural\u201d birth without epidurals. Interestingly, we found a 2015 commentary that responds to this 2014 study \u2014 and it was authored by Lim (the lead author of the new study), who rightfully states that, if epidurals do decrease the risk for postpartum depression, then \u201cit could have tremendous ramifications on the long-term mental well-being of half of the world\u2019s population who are of child-bearing age.\u201d Lim\u2019s letter also called for more research with larger sample sizes to try and replicate the results. But roughly one year later, Lim\u2019s abstract explores the question with no overt controls and a similar sample size.", "answer": 0}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\nThe study tested six formulations of ECP, using different doses of the active ingredients integrated within different meal kit menus, randomized against two U.S. Food and Drug Administration-approved active comparators.\nThe proportion of patients reporting being satisfied or extremely satisfied with the experience of using the lead ECP formulation was nearly double that for those using the standard preps, 64.3% versus 33.3%.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release uses the term \u201cnovel\u201d to describe this new prep formulation. \u00a0Although a variety of preps are now available, this study\u2019s novelty appears to be its high level of patient satisfaction.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the true novelty of the approach?", "explanation": "What appears to be \u201cnew\u201d is the explosion of combing salons and newer prescription shampoos, as well as the review article published last week that evaluates them.", "answer": 1}, {"article": "People seemed to have mental health benefits from physical activity regardless of whether they reported working out to the point of exhaustion or barely breaking a sweat.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\nAt the start, about 12% said they didn\u2019t exercise, and the rest said they exercised anywhere from \u201cup to 30 minutes\u201d to \u201cmore than 4 hours\u201d a week.\nThe paper, published in the , followed more than 22,000 healthy Norwegian adults without symptoms of anxiety or depression for an average of 11 years, asking them about their exercise habits and symptoms of depression and anxiety at the beginning and end of the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Exercise for mental health is not a new concept. What makes this study novel is that it\u2019s looking at exercise\u2019s potential to prevent depression, and if that impact would be useful enough for a public health level initiative. As the study explains:\n\u201cWhile many agencies are keen to promote the potential mental health benefits of exercise, at present the literature is unable to provide the most basic information needed for effective, targeted, evidence-based public health campaigns concerning depression and anxiety.\u201d\nThe story didn\u2019t explain this.", "answer": 0}, {"article": "There was still a benefit four weeks later.\n\"The amount of additional sleep was not tremendous,\" said Dr. Carl Bazil, director of the division of epilepsy and sleep at New York-Presbyterian Hospital/Columbia University Medical Center.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\nThere are still many questions, including whether the drug would benefit people with insomnia due to a health condition, which doctors call secondary insomnia.\nThe study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One of the independent experts addressed the drug\u2019s relative novelty in this section:\n\u201csuvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\n\u201cThe way [suvorexant] works makes a lot of sense,\u201d Bazil said. \u201cThe hope is that it will help some people who haven\u2019t responded to [other drugs], and have fewer side effects.\u201d", "answer": 1}, {"article": "Has he had any use of prescription painkillers since he started the study?\n\"They make you feel great; I'm not going to lie, you take a couple pills, you feel relaxed, you don't feel nervous, you have the weight of the world off your shoulders,\" said one young man named Brian who would not letreveal his identity.\nSuboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\n\"When you're taking Suboxone, you're not high, you're not in withdrawal, you're at work, you're dealing with your loved ones, you're having regular interactions...you're going about your life,\" Gourevitch said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment in places implies the drug is new and novel (by referring to the current clinical trial, by using the word \"new\" to describe it, and by emphasizing its hope for revolutionalizing treatment). But it also states that it is currently available. This leaves the viewer uncertain about what\u2019s \"new\" here.\nSo what is new? Buprenorphine has been an approved parenteral analgesic for decades. The drug was approved in 2002 as an alternative to methadone\u2013a drug to be taken as a more benign replacement for the more addicting drug being abused, such as heroin. It enables withdrawal from the addicitive drug, which may be followed by other addiction treatments or maintenance therapy.\u00a0 \nThe current trial involves only patients who are addicted to painkiller medications like OxyContin. The study is designed to determine whether those taking Suboxone and getting supportive counseling can taper off Suboxone fairly quickly and become entirely drug-free.\u00a0\u00a0 ", "answer": 0}, {"article": "Moskowitz and colleagues designed the tools based on evidence showing these particular skills increase positive emotions.\n\"Even in the midst of this stressful experience of testing positive for HIV, coaching people to feel happy, calm and satisfied -- what we call positive affect -- appears to influence important health outcomes,\" said lead author Judith Moskowitz, professor of medical social sciences and director of research at the Osher Center for Integrative Medicine at Northwestern University Feinberg School of Medicine.\nSome of the skills included:\n\n1) Recognizing a positive event each day \n\n2) Savoring that positive event and logging it in a journal or telling someone about it \n\n3) Starting a daily gratitude journal \n\n4) Listing a personal strength each day and noting how you used this strength recently \n\n5) Setting an attainable goal each day and noting your progress \n\n6) Reporting a relatively minor stressor each day, then listing ways in which the event can be positively reappraised.\nThis can lead to increased positive affect in the face of stress \n\n7) Understanding small acts of kindness can have a big impact on positive emotion and practicing a small act of kindness each day \n\n8) Practicing mindfulness with a daily 10-minute breathing exercise, concentrating on the breath\n\nFifteen months after the interventions, 91 percent of the intervention group had a suppressed viral load compared to 76 percent of the control group.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release contains this claim of novelty:\n\u201cThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\u201d\nWe believe others in medicine have probably used \u201cpositive\u201d intervention before, but they may have called it support or emotional coaching or many other phrases. Cognitive-behavioral therapy, massage, and other means to improve a person\u2019s coping skills could be considered \u201cpositive emotion intervention.\u201d", "answer": 0}, {"article": "May 4, 2010 (New York) -- An experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure, one of the main health consequences of obesity, according to new research presented at the American Society of Hypertension\u2019s 25th annual meeting in New York.\nThe new analysis of three separate studies included more than 4,500 people.\nOparil is a consultant for Qnexa manufacturer Vivus.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story reported that the drug was a combination of two commercially available medications. \u00a0", "answer": 1}, {"article": "TUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nThe system might also make colon cancer screening more efficient and boost the number of people who get checked for the disease, said a team led by Dr. Thomas Imperiale of Indiana University Medical Center, in Indianapolis.\nSo, patients scoring at the lower end of risk for colon cancer might be able to have less invasive screening tests (such as the fecal occult blood test), while those at higher risk would require a colonoscopy, Imperiale's team concluded.\nThey calculated a clinical \"score\" for each of these patients, based on their health information, and the five most common risk factors for colon cancer: age, sex, waist size, smoking and family history.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound as if this is a first-of-its-kind tool. However, risk calculation tools for colon cancer have been in circulation for many years.", "answer": 0}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAs a result, doctors have been looking for a product to make new stretch marks look and feel better, Draelos says.\nMarch 11, 2010 (Miami Beach, Fla.) -- A moisturizing cream whose active ingredient is extract of onion can help take the redness out of new stretch marks.\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many creams that combine moisturizers and plant extracts and claim to treat skin problems.\u00a0This story should have challenged the notion that adding\u00a0onion extract to a skin\u00a0cream makes it\u00a0in any way \"new.\" \u00a0\u00a0\u00a0", "answer": 0}, {"article": "\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\nThe light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria not exposed to light remained active.\n\u201cWe\u2019ve known for a century that UV light is extremely efficient at killing microbes, bacteria, and viruses,\u201d says study leader David Brenner, director of the Center for Radiological Research at Columbia University Irving Medical Center.\n\u201cNo matter how well you sterilize a room beforehand, the medical staff can still bring in dangerous bacteria like MRSA,\u201d says Brenner.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is made clear the authors have studied this type of light in killing methicillin-resistant staph. aureus (MRSA), but it\u2019s not clear if the current study is the first to apply far-UVC light to an influenza virus (in the published study the authors claim this is the first time far-UVC light has been assessed for inactivating aerosolized viruses).", "answer": 0}, {"article": "March 4, 2010 -- A new urine test may reduce unnecessary biopsies for prostate cancer.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nAt a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, researchers presented results of the largest study to date of the PCA3 test.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0This story failed to mention that peer reviewed studies examining the utility of PCA3 have not found it to be significantly associated with progression of prostate cancer.\u00a0 Reporting on the results of this recent study, based on information from a company spokesperson without examining what others may have found to date is inadequate.\n", "answer": 0}, {"article": "Dr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\nCeramic hips were promoted as lasting much longer than the 15 years or so for conventional artificial joints made of steel and plastic.\nCeramic materials have been used since the 1960s.\nThe head is attached to a spike that is driven into the femur, or thigh bone, to anchor it.\nEach combination has known or suspected drawbacks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003.", "answer": 1}, {"article": "\"People say, 'What's the harm in screening?'\nThe recommendations come at a time when doctors are increasingly questioning whether many tests, drugs and procedures are being overused, unnecessarily driving up health-care costs and exposing patients to the risks of unneeded treatment.\nThe guidelines address perhaps the most important and contentious issue in men's health, and were praised by officials at several leading medical groups, including the National Cancer Institute and the American Cancer Society.\nIn the first update of its recommendations for prostate cancer screening in five years, the panel that sets government policy on preventive medicine said that the evidence that the test reduces the cancer's death toll is too uncertain to endorse routine use for men at any age, and that the potential harm clearly outweighs any benefits for men age 75 and older.\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was reporting on the release of new guidelines from the US Preventive Services task force, and highlighted that these recommendations differ from the previous version in that they specify that the benefit of routine screening of men older than 75 years of age for prostate cancer is little to none while at the same time, the harms are moderate-to-substantial.", "answer": 1}, {"article": "A video in which Professor Probert explains how the machine works can be found here\n\"The Odoreader has a 30 metre column that enables the compounds in the urine to travel through at different rates thus breaking the sample into a readable format.\n'The use of a gas chromatography (GC)-sensor system combined with advanced statistical methods towards the diagnosis of urological malignancies', published today in the Journal of Breath Research, describes a diagnostic test using a special tool to 'smell' the cancer in men's urine.\nThe results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.\nWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device is similar to many other technologies in development that are said to \u201csniff\u201d cancer based on specific odor signatures. But the release makes it sound as though this device is unique.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Pap smears rely on using a microscope to hunt for cancer cells, whereas the newer methods described use genetic testing. The story also notes how ultrasound and genetic blood tests for uterine cancers typically are used only when symptoms arise \u2014 an advanced stage of the cancers \u2014 since the those tests \u201cfail to detect many cancers, and also send up a lot of false alarms.\u201d The article places extra emphasis on so-called \u201cliquid biopsies,\u201d saying thy \u201chold the promise of revolutionizing cancer screening\u201d due to a lack of early screenings for these cancers. (That remains to be seen.)", "answer": 1}, {"article": "Dec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\nThe women remained cancer-free for an average of seven months -- results unheard of in patients this sick, he says.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the novelty of the compound as a combination of an existing drug and a derivation of an older, abandoned drug. It also describes that there are other ongoing studies of T-DM1.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the new recommendations represent a departure from existing guidelines.", "answer": 1}, {"article": "For more information, visit http://www.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nIn 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nIn addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not make clear that urine and breath tests have existed and been used for breast cancer, but the novel part of this study is the statistical analysis and modeling.", "answer": 0}, {"article": "That\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nThe new study provides further evidence of that.\nCT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nLung cancer kills more people in the U.S. than any other cancer \u2014 over 150,000 each year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story put the new study in the context of other research in this field.", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\nIn such cases the drug is temporarily discontinued and reintroduced at a lower dose.\nThe lower their neutrophil count, the more vulnerable patients are to infectious diseases.\nAlthough, median progression-free survival was four months, five patients had progression-free survival greater than one year.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The drug is the first of a new class of drugs and that\u2019s noted in the release. ", "answer": 1}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\n\"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor,\" said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\nTUESDAY, Nov. 16, 2010 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThis gene therapy technique is indeed something new, but the story would have been better if it had included some independent assessment of a researcher\u2019s claim that, \u201cThis is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure.\u201d \nAlso, the researchers reported very similar results at other heart failure meetings last summer. The story does not make clear that this latest announcement merely adds a few more months of follow-up, not entirely new results.", "answer": 1}, {"article": "Vincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nThe study of acupuncture as a remedy for hot flashes was sparked by reports from women who had undergone the ancient Chinese therapy for other problems and reported that their hot flashes seemed to moderate.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\n\"We were hoping for something better,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Article notes that acupuncture has been used for more than 2,000 years.", "answer": 1}, {"article": "Muscles all over the body break down as the patient grows up, the heart included.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThe story reports the new finding of this study in its next-to-last sentence, while leading with old news. The researchers wrote that to their knowledge \u201cthis is the first report of rapid reversal by a drug treatment of the functional symptoms seen in the established cardiac dysfunction that occurs in mdx mice.\u201d But the story lead is that the drug \u201cmight help treat heart symptoms of muscular dystrophy\u201d\u2026 something that has been reported previously not only in mice, but is already being tested in people. This story does not appear to put this latest study in the proper context of other experiments.\nReference:Revatio for Heart Disease in Duchenne Muscular Dystrophy (REVERSE-DMD)http://clinicaltrials.gov/show/NCT01168908", "answer": 0}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A bit of historical information in the story makes it clear that online therapeutic agents have been around\u2014in various stages of development\u2014for more than a decade.", "answer": 1}, {"article": "TUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\nAs part of an ongoing study, 179 women underwent breast ultrasound and elastography.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nThe U.S. National Cancer Institute has more about cancer diagnosis.\nElastography measures the compressibility and mechanical properties of a lesion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately describes the novelty of elastography.", "answer": 1}, {"article": "\"If your immune system has been educated by the vaccine to recognize the tumor cells, we think it will allow the immune system to take care of any individual [cancer] cells trying to set up shop,\" explained Dr. Elizabeth Mittendorf, a surgical oncologist at the University of Texas M.D.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\n\"Whether it actually has an increase in survival remains to be seen,\" he said.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\nPhase 3 studies are needed before the vaccine could be approved.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study\u201d but didn\u2019t explain how the vaccine in question is different than any of those other approaches.", "answer": 0}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nThere are women who are alive today because of this drug,\" says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that tucatinib is unusual because it is taken in pill form, meaning women do not need to visit infusion centers for treatment. It also suggests that tucatinib is unusual because of its small molecular size, enabling the drug to pass the blood-brain barrier. However, no information is provided about how many, or how few, other cancer drugs can be taken in pill form or whether any other anti-cancer drugs currently in use or in testing also can pass through the blood-brain barrier.", "answer": 1}, {"article": "STOCKHOLM (Reuters) - Giving patients with a history of heart attacks a margarine enriched with omega-3 oils in addition to standard drugs appears to make no difference to their chances of having a repeat attack.\nThe finding raised questions about the benefits of omega-3, which has been shown in previous studies to make for healthier hearts.\n\u201cWe found the cardiovascular mortality rate in the study population was only half that expected, probably because of their excellent treatment,\u201d he said.\nThey were randomly assigned use of one of four margarines on bread instead of their regular spread \u2014 one containing no extra omega-3 fatty acids; one with 400 milligrams a day of extra eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); one with 2 grams of alpha-linolenic acid (ALA); and one with a combination of EPA-DHA and ALA.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0Although the product being tested was indeed novel as the story indicated, the story was reported from the standpoint of possible impact the results of the study might have on dietary recommendations or the use of n-3 fatty acid supplements.", "answer": 1}, {"article": "Anal cancer that has spread to lymph nodes is linked to a worse prognosis and lower chance of survival.\nThe project's findings however have uncovered a phenomenon suggesting rates of lymph node spread are being overestimated, potentially leading to overtreatment of patients with chemo radiotherapy.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\nShe said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release is fairly clear that the meta-analysis has uncovered/confirmed that statistical misinformation can result from even the best intentioned efforts to improve diagnostic criteria and staging. It would have helped for the release to connect the dots and demonstrate what those data are and what their impact would have on various patients.", "answer": 1}, {"article": "All were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nHalf of these low-risk patients received stents and medication.\nAbout 1.2 million angioplasties are done in the United States each year.\nHalf of the participants also were assigned to get angioplasty.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that stenting is not a new idea.", "answer": 1}, {"article": "The other co-authors were from the CDC.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nThe study was funded by grants R21-DK112066, R01-HL093009 and ULI-TR001422 from the National Center for Health Statistics of the National Institute of Health.\n\"This seems like a no-brainer to screen patients who have any of these additional risk factors,\" said lead author Dr. Matthew O'Brien, assistant professor of medicine at Northwestern University Feinberg School of Medicine.\n\"The earlier patients are diagnosed with these conditions, the sooner they can begin to combat them,\" O'Brien said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study is the first to \u201creport on how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\u201d It also mentions that the research builds the study author\u2019s previous work. As noted above, the release should have included more hard data from the study to back up its argument. ", "answer": 1}, {"article": "Then what, Dr. Nigg asked in series of studies, do orthotics actually do?\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\nIn one study discussed in his new book, \u201cBiomechanics of Sport Shoes,\u201d Dr. Nigg sent a talented distance runner to five certified orthotics makers.\nBut they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The shoe inserts described in this study are widely available and are not particularly novel in concept or design. The article did not \u201chype\u201d particular orthotics because of innovative characteristics or qualities.\n\u00a0\n", "answer": 1}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nMore attractive to many men than a long-acting injection or topical gel\u2014both of which are in development\u2014the prototype pill offers a \u201cmajor step forward\u201d in male contraception, Stephanie Page, a professor at the University of Washington in Seattle and senior investigator on the study, said in a statement.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A 1980 journal article trumpeted \u201cChina Invents Male Birth Control Pill.\u201d 2003 saw the publication of a book titled \u201cThe Male Pill: A Biography of a Technology in the Making.\u201d As recently as 2016, news releases have talked about research such as \u201cmale birth control shots\u201d that \u201cprevent pregnancy\u201d (we reviewed that one). In short, research into pharmaceutical contraceptives for men has been an active field for decades \u2014 and premature announcements of breakthroughs date back at least 38 years. This story quotes a researcher involved in the recent study as saying the findings are a \u201cmajor step forward\u201d and are \u201cunprecedented in the development of a prototype male pill.\u201d But it doesn\u2019t tell us why. What makes this study, or this pill, different?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the popularity of knee replacement is expanding from older people to younger ones, suggesting that the operation is not new.", "answer": 1}, {"article": "Johnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested formulations that are made by pharmaceutical companies and approved by the Food and Drug Administration, whether the hormones come from plants or equine sources.\nFor one thing, the conclusions of the study have been discredited by subsequent studies.\nSuch custom compounds are not FDA-approved.\nToo many women have been taught to accept suffering in this stage of life, they say.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about the approaches described in the story.", "answer": 2}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is not novel. Most readers likely know that nonoperative treatments such as pain medications and physical therapy are not new.", "answer": 1}, {"article": "So she started her own company.\nThe Fertilome test can help you decide if it is right for you.\u201d\n\nThe company\u2019s website also features testimonials from women who say they have used Fertilome to help guide their decisions.\nThe Fertilome test, which must be ordered by a doctor, analyzes a woman\u2019s DNA for 49 genetic variants that have been linked to various conditions that can sometimes cause fertility problems.\nPetrozza said he worries that women might wrongly interpret a long litany of genetic risks to mean that their hopes to start a family are \u201cdoomed.\u201d He also said he sees the test as \u201cvery costly for what it\u2019s trying to do \u2014 and not really giving, at least at this point, what I would consider meaningful information.\u201d\n\nThe Fertilome test was eight years in the making.\nWithout the proper context, \u201csome of this can be very misleading and very frightening to patients,\u201d said Dr. John Petrozza, chief of the division of reproductive medicine at Massachusetts General Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Many fertility clinics offer genetic testing. It is possible that Fertilome is unique to the extent that it looks for nearly 50 genetic variants. But the story doesn\u2019t clearly explain how this is different from other genetic tests that may be offered to help couples conceive.", "answer": 0}, {"article": "Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nSome small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.\nPerhaps the most important question is what the results mean for postmenopausal women.\nShe is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This criterion was adequately addressed as the new additional information provided by this study was made clear.", "answer": 1}, {"article": "Those conditions, sometimes called noninvasive breast cancers, are L.C.I.S.\nThe concern is that many women would have to take tamoxifen or raloxifene for a few to benefit.\nAnother issue is that the message from the cancer institute seemed to play down a shortcoming of raloxifene that cancer doctors consider important.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nA closer look at the recent study suggests that raloxifene's advantages may not be as great as the government announcement implied.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that raloxifene is an existing drug but that Eli Lilly is asking the FDA to approve it for another purpose.", "answer": 1}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nPresented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study.\n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that vegetables, fruits, whole grains, and healthy fats should be recommended for weight loss is hardly new. And yet the release frames these results as \u201cpotentially [leading] to a breakthrough in personalized nutrition.\u201d We\u2019d need more proof of tangible benefits before agreeing with that characterization.\u00a0", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly notes that these techniques were originally developed for use in brain surgeries, but are now being considered for use in a variety of other procedures \u2014 and have been since at least 2011.", "answer": 1}, {"article": "TUESDAY, Nov. 27, 2018 (HealthDay News) --What if a simple zap to the spine could relieve the debilitating lower back and leg pain brought on by a herniated disk?\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nThe process, said Napoli, requires no hospital stay, is noninvasive, far cheaper and less risky.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nBut recent advances in CT scan technology now enable clinicians to deploy those energy pulses with much more accuracy, experts said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains early on that pRT is \u201cnot new\u201d although it\u2019s claimed that recent technology advances enable doctors to deploy it with better accuracy.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The broadcast did lay out for viewers that currently, it is only after death that Alzehimer\u2019s disease can be definitely diagnosed and so if this test were demonstrated to be valid, it would represent something new.", "answer": 1}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\n\"This is the first instance of therapeutic regeneration,\" says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute.\nTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \"had to have a significant amount of damage to begin with and weren't squeezing [blood into the body] as well as they should have,\" says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\nA total of 25 patients participated in the clinical trial, which was designed to determine if it was safe to have cells grown from one's own heart tissue injected back into the heart.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story improves on a competing WebMD story by explaining the novelty of this study. \u201cThis is the first instance of therapeutic regeneration,\u201d says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute. He says while nature abounds with examples of spontaneous regeneration of limbs or tissues \u2013 like a salamander\u2019s new tail or a human liver regrowing to full size if partially damaged \u2013 doctors have not been able to help patients regrow heart tissue. This could change in the future if larger clinical trials and longer patient outcomes confirm the results of this early research published Monday in the journal The Lancet.\u00a0 Marb\u00e1n and his colleagues first presented this research at an American Heart Association conference in November.\n\u00a0", "answer": 1}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story summarizes the results of the study without inflating the novelty of the approach. However, it would have been helpful to provide some background pointing out that there have been other studies that also explored the use of spinal fluid tests to aid Alzheimer\u2019s diagnosis and that proposed guidelines already include using spinal fluid tests to help clinicians identify the likely cause of memory problems in patients.", "answer": 0}, {"article": "(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nOral medicines can be used to systemically limit sweating.\nThe first line of defense are anti-perspirants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no unfounded claims about novelty, and the story makes it clear that an effective topical treatment via wipes would be new for this condition.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This ties in to what we said above regarding alternatives. By explaining several surgical interventions that address uterine fibroids, the story clearly articulates what is novel about the Sonata approach. Well done.", "answer": 1}, {"article": "For more information, visit http://www.\n\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\nThe Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties.\n\"The cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\" said Dr. Wanna.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t tell us anything about the novelty of the wireless cochlear implants nor that of the \u201cround window\u201d (where surgeons open the membrane without bone removal or drilling in the inner ear) and \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear). \u00a0Are these new procedures? \u00a0What other research has been done on them? \u00a0Where is the context that establishes the place of these in the current landscape of hearing-preservation technologies?", "answer": 0}, {"article": "The researchers estimate that as many as 200,000 patients are likely to be living with metastatic breast cancer today in the United States.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nThere is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release made it seem that neratinib was an experimental drug that could be used for women with a particular gene mutation related to HER2+ metastatic breast cancer. It wasn\u2019t made clear that neratinib is already used to treat early-stage HER2+ breast cancer.", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\nRome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t establish novelty. The implication is that the approach is new, but is this the very first time that such a strategy has been tested? If so, where did the idea come from? If not, what did previous studies of this approach find? A bit of background would have been useful.", "answer": 0}, {"article": "Maia Szalavitz is a health writer at TIME.com.\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\nFor example, they like to line up their toys and they get very bent out of shape if there is any deviation.\u201d\n\nMORE: What Does a 400% Increase in Antidepressant Use Really Mean?\nThey\u2019re more able to go outside their comfort zone and to better resist their habits and rituals.\u201d One participant in Hollander\u2019s study was previously too anxious to take the subway or eat in a restaurant, but, when taking Prozac, was able to tolerate these unpredictable environments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the finding is at least implied.\u00a0 This small study increases the number of patients studied in randomized clinical trials by about 15% and it is in adults.\u00a0 With the exception of the earlier RCT published in Archives Gen Psy (N=149) \u2013 in children \u2013 there are just a handful of small studies on this topic.\n\u00a0", "answer": 1}, {"article": "The patient blows a single breath into a specialized balloon.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\nBousamra, van Berkel, and Fu disclose a financial relationship with Breath Diagnostics, Inc.\n\nFor a copy of The Annals article, contact Jennifer Bagley at 312-202-5865 or jbagley@sts.org.\nThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels in the control group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a strong claim of novelty \u2014 and that\u2019s appropriate.\nA quick online search found that besides this research from the University of Louisville in Kentucky, at least two other institutions are developing breath tests for lung cancer detection: Georgia Institute of Technology and the Winship Cancer Institute of Emory University\u00a0 and the University of Leicester.\nThe release said \u201cA subset of four VOCs\u2014called carbonyl compounds because of their carbon base\u2014have been discovered in the exhaled breath of lung cancer patients.\u201d Discoveries sound novel. But this study, more than a decade old, describes the use of VOCs for lung cancer detection. \nWhile the release doesn\u2019t claim to be \u201cfirst,\u201d it might have mentioned related work that has been done in this field of research.", "answer": 0}, {"article": "WEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nThe U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about hip replacement.\nOsteoarthritis, which is usually felt only in the joints, is caused by wear and tear on the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty was not at issue.", "answer": 2}, {"article": "2018;59:160-172.\nThe researchers speculate that it may be due to the polyphenols (anthocyanins and other flavonoids) in Montmorency tart cherries, the varietal of tart cherries grown in the U.S. Polyphenols in plant-based foods are broken down by microbes to stimulate growth of good bacteria.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nIn the human trial, the microbiome was positively altered (primarily measured by the increase in good bacteria) after just five days of drinking Montmorency tart cherry concentrate, although there were strikingly different responses due to the participants' initial microbiome composition.\nLANSING, Mich. August 7, 2018 - Montmorency tart cherries may play a role in improving gut health, suggests a first-of-its kind human trial of nine adults combined with a parallel laboratory study published in the Journal of Nutritional Biochemistry.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions the study is \u201ca first-of-its-kind trial\u201d of humans combined with a parallel laboratory study.\nIt\u2019s mentioned in the published study that, to the authors\u2019 knowledge, this is the \u201cfirst microbiota/metabolome investigation of the impact and fate of tart cherries and their polyphenols in the human colon.\u201d", "answer": 1}, {"article": "Fetal death, or intrauterine fetal demise (IUFD), affects 30,000 women each year in the United States.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\nTo determine whether a woman's endometrium (uterine lining) is healthy and can sustain the embryo, the research team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release doesn\u2019t establish the novelty of this approach. Other research studies have looked at the use of progesterone in preventing miscarriages.\nAccording to the reference site \u201cUpToDate\u201d by medical publishers Wolter Kluwer, more than 50 research studies have examined the use of progesterone in preventing miscarriage or pre-term birth, with mixed results.", "answer": 0}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\n\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article doesn\u2019t explain how the inhaler technology differs from that used in Exubera, only that Afrezza is a dry powder dissolved in the lungs, absorbed into the bloodstream. \nAlso, from what we can see, the overall therapeutic role of Afrezza is no different than that of Exubera. People who need to take insulin to treat their diabetes would need injections of long-acting (basal) insulin and then puffs of mealtime (prandial) insulin. From what we are told in this story, the true novelty of Afrezza over Exubera would be a) its shorter mechanism of action and b) the fact that Exubera has ceased to be. They haven\u2019t demonstrated that Afrezza has a different safety profile in humans from that of Exubera. (Other sources we found quote Dr. Leone-Bay noting that the Afrezza inhaler has unique properties.) The claim of superior glucose control over injectable insulin is unsubstantiated in the story, yet it\u2019s critical information.", "answer": 0}, {"article": "Buysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\nAnd if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\n\u201cGenerally, the most expedient thing to do is just prescribe a sleeping pill,\u201d noted Neylan.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThis story suggests that there are no brief behavioral interventions available to people with insomnia. They story should not have suggested that the only alternative treatments are drugs and expensive cognitive behavioral therapy. ", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research.", "answer": 1}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nThe researchers say 63% of the women who received depression-specific acupuncture reported a significant reduction in symptoms, compared to 44% of women in the other two groups combined.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While prior research\u00a0has studied the effects of acupuncture on depression, it\u2019s still a novel treatment approach. Unfortunately, we can\u2019t tell this from the story. \n\u00a0\n\u00a0", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that researchers are exploring a new use of an existing product.\u00a0 ", "answer": 1}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\n\"At those ages, any benefit we get from moderate drinking is only to the extent that someone who is moderately drinking is not heavily drinking,\" Mukamal says.\n\"I cannot prove and I don't think anyone can prove that alcohol consumption can prevent anyone from dying or prevent heart attacks,\" says Kenneth Mukamal, an associate professor of medicine at Harvard Medical School, Boston.\nThe idea that alcohol might be good for our hearts and blood vessels is a popular one, right up there with the notion that chocolate is a health food.\n\"There may be some evidence that perhaps one glass with a meal is OK,\" says Demetrius Lopes, a neurological surgeon at Rush University Medical Center, Chicago, and another spokesperson the heart association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report briefly went into how a couple of recent studies may be challenging the claim that alcohol is good for your heart. But it didn\u2019t give much background on why these studies differ from dozens of previous studies that have reported potential benefits of moderate alcohol consumption. Researchers argue that participants were poorly selected or grouped in the past. A bit more discussion on this issue in the story would have been welcome.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly indicates that this is the first large-scale study to evaluate the role of statins in increasing survival associated with the flu. The story also mentions previous research, which found that statins can improve survival from other infectious diseases.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that CAD is a newer method of reading mammographies, but in a recent observational trial it was no better\u2013and may have produced more false positives\u2013than images read and interpreted by radiologists alone.", "answer": 1}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\nAn imbalance in serotonin levels is believed to be linked to depression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Some research has been published about electroacupuncture for mental illness \u2013 including by this same research group \u2013 yet the story didn\u2019t hint at any of it.", "answer": 0}, {"article": "Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\nThe single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\nThe main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty here:\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nThe study he led randomly assigned 395 men and women ages 65 to 84 with mild functional limitations to receive either sugar pills or various oral doses of the growth hormone stimulator capromorelin, an investigational medication developed by Pfizer Global Research and Development.\n\"There are no short-term fixes,\" he said, saying diet and exercise remain preferred approaches to avoiding many health problems associated with aging.\nBut \"the line between disease and the disability baggage that accompanies aging is sort of arbitrary,\" he said, pointing out that many interventions, such as prescribing glasses, have been developed to counteract the effects of aging.\nWhile he called his study's findings encouraging, Dr. Merriam declined to characterize them as a breakthrough, saying more work is needed to determine both the safety and the benefits of the treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Promoting growth hormone to counteract the effects of aging, namely physical functioning, is not new. However, the benefit of this has not been established and safety of growth hormone for this use in older adults in unknown. The story does note that this study does not represent a breakthrough in preventing age-related decline in physical or cognitive functioning. ", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nThe direct clinical benefit of temporarily increasing tear production as a therapy for patients with dry eye disease was not assessed as part of these clinical trials.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nTrueTear\u2122 is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears.\nThe new advancement is an addition to Allergan's current eye care portfolio.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this is the first neurostimulator intended to increase tear production in patients with dry eye problems.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nJan. 11, 2011 -- The herpes zoster vaccine, better known as the shingles vaccine and recommended for adults 60 and older, cuts the risk of getting the painful disease by 55%, new research finds.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story makes clear that this is the only vaccine approved to reduce the risk of shingles and that it has been available in the United States since 2006. However, it fails to explain what is new about the information provided by this study. The other stories we reviewed (HealthDay and Reuters) explained that this study offers a glimpse at how the vaccine is performing in the real world, as opposed to the idealized conditions of the clinical trial that led to the vaccine\u2019s approval.", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\n(fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook here is that results of this\u00a0study are billed as \u201cconfirmation\u201d of benefits \u2014 an overstatement \u2014 but also that the study is one of the first undertaken with scientific rigor. It\u2019s hard to say if that is so, but the release makes a reasonable case, albeit based on a very brief trial.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "Described within this story as \u2018a new device\u2019 and that \u2018about 100 hospitals around the country already are using the treatment\u2019 which suggest that this is a relatively new approach.", "answer": 1}, {"article": "The average age of the participants was 11.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nMONDAY, Dec. 7, 2015 (HealthDay News) -- Evidence is mounting that a marijuana-derived oil might benefit some children with epilepsy whose seizures aren't controlled by approved medications, two new studies show.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\nHowever, the oil appeared to interact negatively with two other drugs, clobazam (Onfi) and carbamazepine (Tegretol), the University of Utah researchers found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since cannabis has been used for the treatment of seizures for centuries, it\u2019s curious why the researchers didn\u2019t test the compound in a better designed trial (randomized, blinded and placebo controlled). The public and patients are still left with the question of whether this works. But the story does briefly mention previous studies that have looked at cannibidiol in adults, so the story gets a pass here.", "answer": 1}, {"article": "But two days later, most patients were satisfied.\n\"Emergency nurses and doctors need a variety of pain-relieving options when treating patients, given the concerns around opioids such as morphine, which carry the risk of addiction when used long-term,\" Cohen said in a university news release.\nOverall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It would be pretty novel if the study had shown that acupuncture was more effective than conventional analgesic drugs in controlling pain, but that\u2019s not what this study showed. While\u00a0both the study and the story\u00a0did seem to indicate that acupuncture was as effective as either painkillers or painkillers and acupuncture, the\u00a0abstract of the study\u00a0also said \u201cnone of the examined therapies provided optimal acute analgesia.\u201d Controlling pain was arguably the reason the study\u2019s patients went to the emergency departments. The study basically said acupuncture was as good as painkillers for pain control but that for these patients, neither was successful. We think that should have been explained in the story to help establish the novelty of this research.", "answer": 0}, {"article": "Or she could allow doctors to implant two long, thin electrodes deep into her brain, along with an electrical generator about the size of an iPod in her chest.\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\nThe six-month study, which involved 255 people, found that those who underwent surgery had 4.6 more hours each day of good control of their symptoms than those who got the best drug therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the lede implies the surgery is exotic, later in the story the report makes clear that it is done with some regularity and is being studied for use on other conditions. \nThe reporter includes specifics: About 15 percent of Parkinson\u2019s patients may qualify for the surgery, yet only 2 percent of patients get it. \nIdeally this information would have been placed higher in the story so Parkinson\u2019s patients and caretakers understand the limited applicability.\u00a0 ", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "The study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\nPeople might ask for a test even when they don't show any signs of dementia, and \"this may result in anxiety and depression if there is a false positive result,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research discussed here is novel in a general sense, but the story doesn\u2019t establish this to a satisfactory degree. A number of previous studies have looked at saliva markers of Alzheimer\u2019s, and there are probably dozens of other blood tests, scans, and other approaches currently in development to address the diagnosis of Alzheimer\u2019s disease. The story does not allude to this research", "answer": 0}, {"article": "The findings appeared online Feb. 5 in the BMJ.\n\"And so, we were interested in trying to evaluate just one of these compounds, linoleic acid, by looking at this old trial using modern statistical methods, and also by re-including some original data that had gone missing from the first analysis,\" Ramsden explained.\n\"There is more than one type of polyunsaturated fatty acid,\" explained Dr. Christopher Ramsden, who headed the re-analysis and is a clinical investigator with the laboratory of membrane biophysics and biochemistry at the National Institute on Alcohol Abuse and Alcoholism, part of the U.S. National Institutes of Health.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It has long been known that the\u00a0subjects in the linoleic acid/safflower oil group of this study had higher all-cause mortality. What was unclear is if they had higher cardiovascular mortality.\u00a0The results are not quite as novel as the story suggests.\u00a0 Nonethless, we\u2019ll give the story the benefit of the doubt on capturing the overall gist of the novelty of the study adequately.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThere is no claim of novelty in this story. However, the story fails to make clear how this study was different from other research on this topic.", "answer": 2}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\nwere it not for its high cost.\nIt reviewed the clinical trial data and then rated the strength of the data on a scale of 1 to 5.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear about the novelty of the two drugs presented.", "answer": 1}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that using a follow-on booster of the high-dose vaccine is a novel flu prevention strategy in patients with cancers that affect the immune system. This approach of adding a booster is used in immune-suppressed patients with\u00a0other vaccines as well.", "answer": 1}, {"article": "\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department.\nThe overwhelming majority of these patients do not have a heart attack.\nVery high levels of troponin are a sign that a heart attack has occurred.\nEven a slight increase in the troponin level will often mean there has been some damage to the heart.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook for this release is pretty well established.", "answer": 1}, {"article": "Of those taking an inert pill, or placebo, 91 percent did.\nIf you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\n\nDr. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society cautioned, however, that \u201cone has to be cautious in interpreting these results,\u201d partly because \u201cbased on what they show, there is no overall change in survival.\u201d\nStill, said Dr. Richard Schilsky, who serves as the chief medical officer of ASCO and who was not involved in the study, \u201cthere\u2019s a substantial benefit\u201d to continuing aromatase inhibitors out to 10 years to lower the chance of cancer developing in the other breast.\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately establishes the novelty of the study:\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\n\u201c\u2026If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\nThis is important because many patients already continue aromatase inhibitors:\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years. There had been no research on whether that was beneficial.", "answer": 1}, {"article": "WEDNESDAY, April 20, 2011 (HealthDay News) -- Researchers have developed a blood test that they say could help physicians predict whether pregnant women will deliver their babies prematurely.\nAbout 10 percent of births are premature, and the rate rises to 30 percent among women who have already had a baby prematurely, Graves said.\nThe researchers developed a screening method that looked for so-called peptide biomarkers in the blood that -- in tandem with several other proteins -- predicted 80 percent to 90 percent of the premature births at 28 weeks of gestation.\nThe test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\n\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story never put the new test into the context of other research attempts to study what to do to predict prematurity. So its real novelty \u2013 and role \u2013 isn\u2019t clearly established.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not the only product under the sun designed to quick-test for gluten, although to be fair, it\u2019s unclear whether another product would be better/worse/as good. A quick online search identified\u00a0a number of consumer kits available. It is unclear why a story focusing specifically on this particular device is news.", "answer": 0}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\nThe supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea of using supplements for PMS is not new, and the authors mention past research on the same topic.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate.\nThey plan further analyses, including two-year follow-up CT scans and a cost-effectiveness comparison of SIJ fusion versus nonsurgical treatment.\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release identifies the study as the first randomized trial of a surgical procedure versus conservative,non-surgical care for SIJ dysfunction.", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\nDeveloped by IceCure Medical (Caesarea, Israel/Memphis, TN), specifically for breast applications, the IceSense3 Cryoablation System\u2122, has a long history of successful treatment of benign breast fibroadenomas.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial.\nIts effectiveness in breast cancer has been proven in a number of smaller studies, including a recent American College of Surgeons Oncology Group (ACOSOG) trial and extensive long-term ongoing, unpublished studies in Japan.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Breast cancer isn\u2019t normally treated with cryoablation, and the release makes this clear. We\u2019re also told the improvements built into ICE3 makes treating cancer with it \u201cmore precise\u201d and reliable.", "answer": 1}, {"article": "But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death.\nWhile cannabis is legal in many U.S. states, the drug is still classified by the Drug Enforcement Administration as a Schedule 1 narcotic (along with heroin and cocaine), which make it very difficult for scientists to conduct clinical trials on people.\n\u201cI\u2019m done with you guys bullying us.\u201d\n\nThen, she took out a bag and dumped the contents on the table: nine months of cancer drugs prescribed to her son, Landon, who was 4 at the time.\nBut there\u2019s also an emerging body of research that suggests marijuana might be effective as a treatment for cancer on its own, or in conjunction with standard therapies.\nFirst, there would be several months of aggressive inpatient chemo and other therapies for what\u2019s known as \u201cremission reduction.\u201d After that, even when blood work showed the disease had entered remission, Landon would need years of chemo and monitoring\u2014called \u201cconsolidation\u201d\u2014to make sure his body wasn\u2019t harboring leukemia cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that people have been using marijuana, including cannabis oil, to treat symptoms and side effects of cancer treatment for some time now. It notes that hypotheses about a direct effect on cancer are relatively new\u2026 and remain to be tested in people.", "answer": 1}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nAcupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "What\u2019s novel about this study is the longer term relief gained from the therapies. The study points this out, but the release doesn\u2019t explicitly mention it.", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nWhen your body clock is off from society\u2019s, scientists call it \u201csocial jet lag.\u201d And like the jet lag from a long journey, it messes with your body.\nOnly five of the 18 studies included these measures, but in two of them, later start time was associated with better (self-reported) feelings of depression and irritability.\nIn 2014, the Academy of Pediatrics wrote that \u201cthe urgency and the magnitude of the problem of sleep loss in adolescents\u201d warranted big changes in school start times.\nBut that has consequences: Around 69 percent of high school students get less than eight hours of sleep on a school night, according to the Centers for Disease Control and Prevention, which puts these teens at risk of negative impacts on health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The reader will learn that the effects of eight or nine hours of sleep a night on teenagers have been demonstrated in other studies. What is novel is the meta-analysis\u2019 reflections on the big picture, which suggests caution in\u00a0making school policy changes on the basis of extant studies.", "answer": 1}, {"article": "MONDAY, Aug. 6, 2012 (HealthDay News) -- Treatment with growth hormone-releasing hormone improves memory and focus in healthy adults and in those who already show some signs of mental decline, new research finds.\nResults of the study are published in the Aug. 6 issue of the Archives of Neurology.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\nThe study volunteers were between 55 and 87 years old, with an average age of 68, according to the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least established that the same team had done prior work with GHRH.", "answer": 1}, {"article": "Other researchers will be analyzing economic data.\nIf successful, the smart device could have a big effect.\nPatients can see what is happening to their own bodies and act accordingly.\nThe big leap forward came a few years ago when device companies figured out how to make transmitters that send data over a broader range, 20 or 30 feet.\nOnce a week, she also measures her weight and blood pressure \u2014 key indicators of heart failure \u2014 and that information is automatically transmitted to her doctor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story wove together information from devices that available \u2013 through those used in clinical trials and those under development.", "answer": 1}, {"article": "Carlson notes that many cognitive intervention studies last one year or less.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe study was supported by the Johns Hopkins Neurobehavioral Research Unit, the National Institutes of Health's National Institute on Aging (P01 AG027735-03), the Alzheimer's Drug Discovery Foundation and the Johns Hopkins Epidemiology and Biostatistics of Aging Research Fellowship (NIA T32AG000247).\nAt the same time, those with larger increases in the brain's volume over two years also saw the greatest improvements on memory tests, showing a direct correlation between brain volume and the reversal of a type of cognitive decline linked to increased risk for Alzheimer's disease.\nThe research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study concept \u2014 a randomized controlled trial of a civic engagement program \u2014 is novel and builds upon findings from a smaller pilot study. However, the release doesn\u2019t establish what is new or different about the study compared with previous research.", "answer": 0}, {"article": "Van Hemelrijck and colleagues studied more than 30,000 men in Sweden with prostate cancer who got hormone therapy between 1997 and 2006, for about three years.\n\"For the vast majority of men, the benefits of hormone therapy are absolutely clear: it can halt the disease or stop it for years,\" she said.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\n\"There is no definitive evidence, though the risk of heart problems is definitely something doctors should consider when prescribing hormone treatment,\" Thun said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story does not explain how this study is different than previous studies on this topic. Indeed, the story ignored the key finding that different hormonal therapies were associated with different heart disease risks, thus raising the possibility that treatment choices could be refined.", "answer": 0}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explain, in broad terms, the novel way in which Keytruda and a competing cancer immunotherapy drug, work. The story also talks about the expected economic impact of cancer immunotherapies broadly. So we\u2019ll give the benefit of the doubt on the rating. However, it\u2019s not clear how many cancer immunotherapy drugs are on the market \u2014 just these two? A dozen? More? The story also doesn\u2019t tell readers how many of these drugs are approved for use against lung cancer. Is it just Keytruda?", "answer": 1}, {"article": "But this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nSome people, including physicians, may decide that the answer remains yes.\nIn the late 1940s, the steroid cortisone, an anti-inflammatory drug, was first synthesized and hailed as a landmark.\nUsing it against an inflammation injury was logical.\nCortisone is an anti-inflammatory medication.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe article specified that steroid injections have been employed for roughly half a century.\n", "answer": 1}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nPrevious studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.\n\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story fails to distinguish between previous reports (that were based on either observational studies of people or experiments in animals) and this report that uses data from human experiments on heart disease prevention, so it is not clear to readers what is new about this latest report.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly oophorectomy is not a new idea.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this is the first trial to show a reduction in major cardiovascular events among patients taking this type of fish oil derivative.", "answer": 1}, {"article": "Those assigned to CPAP wore the device for eight hours a night under continuous supervision by a technician.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n\"Although eight hours of CPAP per night can be difficult to achieve in real-life, our results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction,\" she said.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is one of the main limitations of the release. An online search shows that a number of studies have been done on the impact of CPAP use on patients with prediabetes and on patients with type 2 diabetes. The news release does not make clear how this most recent paper expands on the previous work \u2014 and it is important for releases like this one to place the new study in context.", "answer": 0}, {"article": "\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it?\nThe federal government doesn't require companies to vet health claims with the agency before plastering them on product packaging (as long as the claims are accompanied by a disclaimer about their uncertainty).\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThis phenomenon is known as a \"health halo,\" an aura of healthfulness attached to a product based on labels like \"low-fat\" \"all-natural\" or \"made with whole grains\" that seduces consumers into overeating.\nOne of the most prominent claims, that POM can decrease arterial plaque by 30 percent, was taken from a single pilot study that included just 19 people and was funded by the makers of POM.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that POM is hardly the only juice drink making questionable health claims. VitaminWater, kombucha tea, coconut water, and juice drinks made from acai, goji berry, and mangosteen are all mentioned as promoting health claims on their labels.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nThe relationship between statins and cancer is unclear, but other research exploring the impact of statins at the molecular level suggests that these cholesterol-lowering drugs may help control the development of tumor, as well as tumor growth.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story did not provide insight about the historical context for this work. \u00a0For example, there are studies dating back 20 years raising questions about whether this class of medication influences cancer risk.", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach and of the new study is clear in the story.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\n\"These changes suggest a beneficial effect of dTMS on both weight loss and change in microbiota composition,\" Luzi said.\n\"Our research shows the innovative ability of dTMS in exerting anti-obesity effects through alteration of the gut-brain axis.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release confirms that dTMS has been around for a while and is used to treat other conditions, but highlights that using the procedure to treat obesity is a new area of exploration.", "answer": 1}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cThis was far greater than expected.\nIt is the leading killer of women in the United States, claiming more women each year than men.\nCurrently, 42 million American women are living with heart disease.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It seemed clear from the story that the combination device was not new but that its use had recently been expanded.", "answer": 1}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\n\"I see no moral problem in this basic technique,\" said Richard Doerflinger of the U.S. Conference of Catholic Bishops, a leading opponent of embryonic stems cell research.\n\"The goal is to create cells that are missing or defective in people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach described \u2013 while novel \u2013 is certainly not unique (viral vector for treatment of a chronic disease).\u00a0 Additional comments on the approach used by other reseachers would have added a needed balance.\n\u00a0", "answer": 0}, {"article": "\u2022 Online Press registration process: The online registration deadline has expired, we still accept advance registrations though, but the process is slightly different.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nIndeed, most physical activity guidelines are the same for the middle-aged adults as for the elderly, even though it is estimated that over 60% of the elderly are unable to achieve this same level of exercise.\nDuring that follow-up their level of physical activity was monitored and categorised according to five levels of MET-h values per week: <1; 1-3.74; 3-75-7.49 (equivalent to brisk walking for up to 150 minutes per week, and the recommended activity level); 7.5-15; and >15 MET-h per week.2 Mortality and cardiovascular events were recorded over the follow-up period and associated with exercise levels.\nSuch conclusions have been well examined in the general population, where a recommended exercise program of 30 minutes at least five days a week (or 150 minutes per week) has been shown to reduce the average risk of death by 30 percent.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been numerous studies on the benefits of exercise for the general population. Physicians currently recommend exercising for 30 minutes a day for at least five days a week, which \u201chas been shown to reduce the average risk of death by 30%,\u201d according to an uncited source in the news release.\nWhat\u2019s new, says the news release, is that \u201ca correlation between the level of physical activity and risk of death has not been so clearly determined in the elderly.\u201d\nBut we found these studies online, some going as far back as 1989, that state the association between regular physical activity and decreased mortality in older adults. In addition, recommendations are already in place for older adults, who are urged to exercise moderately and daily by the CDC.\nWe\u2019re not sure why the physical activity recommendations for the elderly warrant revision, as stated by the release, or what exactly is new with this research.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nIn a study published in the American Journal of Cardiology, scientists from the National Heart and Lung Institute at Imperial College London calculated that the reduction in heart disease risk offered by a statin could offset the increase in risk from eating a cheeseburger and a milkshake.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This would definitely be novel, and the story makes that clear. What it does not do, unfortunately, is to emphasize that this wasn\u2019t\u00a0a study\u00a0based on\u00a0people eating fast food and then taking statins. There was only one line very late in the story explaining that the researchers \"used data from a previous large study\" and that they did a comparison \"using data from seven previously published trials.\"\u00a0 ", "answer": 1}, {"article": "\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nDuring the follow-up, there were 8,092 cases of prostate cancer \u2014 significantly fewer in the group who took acetaminophen daily for five years.\nMen who walked briskly \u2014 at a pace of about 3 miles per hour or faster \u2014 at least three hours per week were 57% less likely to experience disease progression (including elevated PSA levels, secondary treatment, bone metastasis or prostate cancer-related death), compared with men who walked less and more slowly.\nIn the first study, published Monday in the journal Cancer Epidemiology, Biomarkers and Prevention, scientists found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing prostate cancer, compared with other men.\n\u201cThe walking had to be brisk for men to experience a benefit.\u201d\n\nThe researchers said the effect of brisk walking persisted independent of age, diagnosis, type of treatment and characteristics of disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that there\u2019s been prior research in both fields \u2013 studying effects of anti-inflammatory drugs and walking on prostate cancer.\nSo it didn\u2019t inappropriately paint either pursuit as totally new.", "answer": 1}, {"article": "Plus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nA study in the journal Facts, Views and Vision found that IVM achieved up to a 35 percent clinical pregnancy rate in young women, which is comparable to IVF.\nAlthough the treatment is used in conjunction with IVF, the initial process isn\u2019t the same.\nAlthough IVF is considered the standard of care, experts say some women may benefit from IVM.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, it\u2019s hard to say just why Fox is presenting this as \u201cnews now.\u201d", "answer": 0}, {"article": "Newswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\nThe reflector replaces the widespread current practice of inserting a thin, hooked wire into the breast the same day as surgery.\nAfter the patient receives a local anesthetic, it can be placed into the breast using an extremely thin needle under image guidance days or weeks prior to surgery.\nThe wire is placed into the breast to help guide the surgeon in removing the abnormality later that day.\nThat advantage may lead to less tissue needing to be removed and a better appearance of the breast after surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the Savi Scout is novel and that Rush is the first institution in Illinois to deploy the technology.", "answer": 1}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\n\u201cThe prototype dressing mimics this physiological process, and while it has proven to create an optimal environment where chronic wounds can heal, we are always looking for new ways to keep pathogens under better control.\u201d\n\nRoy notes that chronic wounds are particularly susceptible to infection because bacteria, which at times are free floating within a wound \u2013 can sometimes mobilize, creating colonies covered by a thick sticky coating called a biofilm.\nBacteria are known to quickly acquire resistance against antibiotics, but to our knowledge, bacteria do not develop resistance against electroceuticals.\u201d To test the experimental design, Roy and a team of scientists developed an animal model to mimic the skin function of a person suffering from metabolic syndrome \u2013 obesity, high blood pressure, high blood sugar - which mirrors the type of patient that typically develops chronic wounds.\n\u201cA wound naturally produces its own electrical fields that help reduce bacteria and promote cell regeneration; however, this function is likely impaired in chronic wounds,\u201d said Sashwati Roy, PhD, an Associate Professor in the Department of Surgery at Ohio State\u2019s College of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As the news release points out,\u00a0FDA-approved\u00a0WEDs already exist on the market. What is the real novelty here? We are told:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\nBut the release never explains what these\u00a0significant advances are.", "answer": 0}, {"article": "None of the participants had serious side effects from the MILs therapy.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nIn a report on what is believed to be the first small clinical trial of its kind, researchers at the Johns Hopkins Kimmel Cancer Center say they have safely used immune cells grown from patients' own bone marrow to treat multiple myeloma, a cancer of white blood cells.\n\"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells,\" says Johns Hopkins immunologist Ivan Borrello, M.D., who led the clinical trial.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We like the fact that the headline itself defines this as a \u201cpilot\u201d clinical trial and that the lede says that it is \u201cwhat is believed to be the first small clinical trial of its kind.\u201d\u00a0 Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings.\u00a0 All too many other medical releases fail to provide this measured approach.", "answer": 1}, {"article": "Santen and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\nThe Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\nHormone therapy may help relieve a woman's menopausal symptoms but is not recommended for women who have had breast cancer.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Besides listing lifestyle approaches which are not novel, it\u2019s unclear if the emerging approaches listed are novel.", "answer": 0}, {"article": "William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nThe brain begins by generating fairly random patterns, while the computer software responds with encouragement whenever the activity meets the target.\nA major attraction of the technique is the hope that it can help patients avoid drugs, which often have side effects.\nSubsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nAt the start of the treatment, Dr. Coben said, he discovered that Peter had been suffering tiny, asymptomatic seizures.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story seemed to provide a nice history of neurofeedback devices from the 1960\u2019s.", "answer": 1}, {"article": "Powerful chemotherapy and radiation treatments for cancer can impair a woman's fertility.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Apparently, it isn\u2019t new to remove an ovary and freeze it. Some of the patients in the study had that done 15 years ago. The story establishes this and explains that the study is new in that it reports on longer-term outcomes.", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a good job of noting that there are other studies past and planned designed to test the value of bariatric surgery compared to other interventions for obesity and diabetes.", "answer": 1}, {"article": "\"The hope for neurofeedback is that after training ends, the benefits that resulted from training will persist -- that in some sense there's been more enduring change in the child's ability to focus and attend and to regulate their behavior,\" he says.\nThe laptop is connected to electrodes applied to the scalp.\nAnd one chapter of the book is devoted to neurofeedback.\nThe results should be out within a few weeks, Arnold says.\nSpecial software monitors the electrical activity in your brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not oversell the novelty of neurofeedback for the treatment of ADHD.", "answer": 1}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\nIt can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\nThere are currently no treatments for Prader-Willi syndrome, the most common genetic cause of life-threatening obesity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Having stated that there are currently no treatments for Prader-Willi, the novelty of the beloranib should be\u00a0self-evident to the reader.", "answer": 1}, {"article": "Dr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nMoreover, they had a 48 percent reduced risk of having an elevated level of prostate-specific antigen, or P.S.A., the protein measured in a common blood test for prostate cancer.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story names the drugs studied\u2013aspirin, naproxen, and ibuprofen\u2013none of which is new to the market. This is a new use of existing medications. ", "answer": 1}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nThe various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.\nIn the event, researchers reported that Merck\u2019s combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that these findings reveal that immunotherapy works better when patients are prescreened for a specific genetic marker known as PD-L1, versus giving it to anyone with this type of cancer. It also\u00a0explains that the smaller second trial, mixing Keytruda with chemotherapy, was \u201cthe first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\u201d", "answer": 1}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\nThey all kept diaries of their hot flashes and filled out questionnaires about various problems tied to menopause, including hot flashes, sweating, insomnia, tiredness and headache.\nHe said it was \u201chard to believe\u201d that soy would have an effect on these women.\nBut doctors and women have become increasingly wary of that option because of serious side effects such as increased risk for heart attack, stroke and breast cancer.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least establishes that there has been other past research on soy supplements and hot flashes, quoting an American researcher.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n\u201cBy detecting those individuals who don't have narrowing in their heart arteries, but they are in the process in developing them because the arteries are inflamed, we may be able to intervene early enough to prevent heart disease.\u201d\n\nThat's why surgeons do heart bypasses.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on the use of inflammatory heart tissue as having potentially better predictive value than current risk assessment tools for heart attack. But it\u2019s a reluctant satisfactory, because the narrative is confusing and no\u00a0numbers were given to estimate the scope of the potential benefit\u2013how well the new approach worked.", "answer": 1}, {"article": "The average age was 53 when the study began.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nAn additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this is a newly published study showing no evidence that a diet high in fruits and vegetables is not directly related to a decreased risk of breast cancer recurrence.\u00a0 Increasing fruits/vegetables in the diet is not a novel concept. ", "answer": 1}, {"article": "Dec. 14, 2012 -- Drinking a glass of beet juice may have an immediate impact on lowering blood pressure , according to a new study.\nBut when researchers limited their analysis to men only, they found a significant reduction of about 4.7 points among those who drank the beetroot juice.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nThe same procedure was repeated two weeks later, with those who drank the placebo on the first round receiving beetroot juice on the second.\nIn the study, 15 men and 15 women drank either 17.6 ounces of a beet juice beverage consisting of about three-fourths beet juice and one-fourth apple juice, or a placebo juice.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that previous research has shown a blood pressure-lowering effect for beet juice in a laboratory setting.", "answer": 1}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\n\"In the short term, what it is designed for is treatment of withdrawal,\" he says.\nThe findings are at odds with clinical trials, Connolly says.\nThe results of the new study are published online in Tobacco Control.\nInstead, he suggests understanding its use.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the new study gives a more \u201creal world\u201d picture of nicotine replacement therapies.", "answer": 1}, {"article": "Lung cancer is the No.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\nTZDs include GlaxoSmithKline\u2019s Avandia, known generically as rosiglitazone, and rival drug Actos, or pioglitazone, made by Takeda Pharmaceutical Co Ltd.\n\nMazzone said it may be possible one day to use metformin to prevent lung cancer in smokers.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nPatients who had taken the drugs to control diabetes were much less likely to have lung cancer spread \u2014 which is when it becomes most deadly \u2014 the researchers told a meeting of the American College of Chest Physicians.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Dr. Mazzone tells us what\u2019s unique and not unique about the study. As we pointed out under the \u201cevidence\u201d criterion, his quote may be the source of some confusion, but he is clear about what\u2019s unique.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was correct in presenting the \"paint\" as a new possible adjunct to the methods used for determining tumor boundaries.", "answer": 1}, {"article": "\"Every day.\"\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nFor years, his only relief was a cocktail of prescribed medications.\nThe idea dates back 2,000 years, when a Roman physician found he could relieve gout and headache by placing an electric fish on the scalp.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment makes clear that while this particular application of electrical stimulation is novel, it has been in development and used for other purposes for many years. ", "answer": 1}, {"article": "Gulley is director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology, National Cancer Institute.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nFor them, the median time before the cancer progressed was about two months.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n\"That time frame is not anything to write home about,\" Gulley says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The concept of vaccines for breast/ovarian cancer is indeed novel, and the story acknowledges that other vaccines are being studied.", "answer": 1}, {"article": "It's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\nTheir study is published in the Dec. 24/31 issue of the journal Nature.\nNon-small cell lung cancer constitutes about 85-90% of lung cancer cases.\nHowever, over time, the tumor cells develop additional mutations, enabling them to grow again, even in the presence of the drugs Iressa or Tarceva.\nLung cancer is the most common cause of cancer death in the U.S. for men and women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the novelty of the compound.", "answer": 1}, {"article": "This, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt also shows that the claims made by anti-vaxxers are wrong, and that people fighting the vaccine because of their own sexual biases are making things far worse.\nFor example, a young girl died tragically not long after getting the vaccine, and it got a lot of press, but it was later found that she died of a completely unrelated cause.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nThat\u2019s why I am very, very clear about this: I and my family are all up to date with our vaccinations, and my daughter has had all three stages of the Gardasil vaccine (we\u2019d have done that if she had been a boy, too).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the study driving the coverage is \u201cnew,\u201d but beyond that doesn\u2019t establish what is different or interesting about this research compared with previous studies.", "answer": 0}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nSome cancers that are found on mammography may not have proven to be an issue in a woman's lifetime.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nOtto's study only looked at women aged 49 and older.\nTo learn more about mammograms, visit the U.S. Department of Health and Human Services.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Screening mammography is not a new approach to detecting breast cancer.", "answer": 2}, {"article": "Marji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n\"When we used the extract from that melon, we saw that it kills the breast cancer cells,\" said lead researcher Ratna Ray, a professor of pathology at Saint Louis University.\n\"Many supplements have biologic activity, but before I recommend that people take isolated supplements they need to be tested in humans.\"\n\"The results of this laboratory study are intriguing,\" McCullough said.\n\"But before recommending bitter melon extract supplements for cancer prevention, we need appropriate clinical trials to establish its safety and efficacy in humans.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There\u2019s been a lot of research for a long time on bitter melon extract.\u00a0 We quickly found one study from as far back as 1983.\u00a0 The story didn\u2019t provide any of that context. ", "answer": 0}, {"article": "The oral drug targets an enzyme called Syk.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead of the story says, \"An experimental rheumatoid arthritis treatment helps two-thirds of patients getting too little relief from methotrexate.\"\u00a0But the story itself fails to explain how these two drugs interact, if at all. If this drug is truly novel, is it a replacement for the other drug or an enhancement?\u00a0Have other drugs been tested in this same vein?\u00a0Are there competitors in trials, too?", "answer": 0}, {"article": "\u201cIt wasn\u2019t effective.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nBotox is currently FDA approved for cosmetic use to lessen frown lines, and for medical use to treat a number of conditions including chronic migraines, bladder incontinence, excessive underarm perspiration, and certain types of neck pain and eye issues.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Botox has already been promoted for \u201coff label\u201d use to treat depression for some time. HealthNewsReview.org has previously explored the marketing of botox for depression and other conditions. Not only is evidence not presented well, but the news isn\u2019t novel, either.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story plainly states that the procedure is increasingly common and widely advertised. It cites figures from the study that demonstrate the increase of use between 2003 and 2005. ", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty in this story is not so much about the treatment itself, which the article states has been a research focus since about the year 2000. The novelty here resides in the scope and expense of these clinical trials. The\u00a0story\u00a0makes that clear.", "answer": 1}, {"article": "SUNDAY, Sept. 30, 2018 (HealthDay News) -- It's a perfect case of the enemy of my enemy is my friend.\nThe potential for Clostridium novyi-NT to prompt an immune response against cancer is intriguing, said Sacha Gnjatic, who is associate director of the Human Immune Monitoring Center at Mount Sinai in New York City.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\nTo test whether the bacteria could help fight cancer, researchers injected the tumors of 24 patients with a single dose of Clostridium novyi-NT, ranging from 10,000 to 3 million spores.\nTwo patients treated with the heaviest dose of 3 million spores of Clostridium novyi-NT fell ill with sepsis and/or gas gangrene, leading researchers to set the maximum tolerated dose at 1 million spores.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty of the research. The abstract describes this as a \u201cfirst-in-man\u201d trial of weakened clostridium novyi spores in cancer patients.\nIn general, though, bacterial therapies for cancer tumors have been studied for decades, although only recently have safer forms been available.", "answer": 0}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\nIt is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.\nA range of clinical trials of SBRT therapy are under way at Simmons Cancer Center, including new investigations evaluating use of SBRT for cancers in the breast and larynx.\nThe findings are published in the European Journal of Cancer.\nIn addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study was the first published trial to follow patients receiving SBRT for five years.", "answer": 1}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nHowever, the study did not prove a cause-and-effect link between earlier mammograms and smaller tumors and less aggressive treatment.\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\nBut this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nStill, \"the observations are consistent with what we have seen with the value of early detection.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear the distinctive aspects of this study \u2014using avoidance of more aggressive treatment regimens as a deciding factor, as opposed to the more extreme avoidance of cancer death.\n", "answer": 1}, {"article": "\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nMost of the patients had an artery blockage greater than 70 percent.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\nThe trial included patients who had suffered a stroke or a ministroke and those who were asymptomatic.\nEach year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that both of these approaches have been in use for quite some time. ", "answer": 1}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThe people who generally do best are those who arrive at the hospital and have angioplasty within 90 minutes of the heart attack.\nThey had the same rates of heart attack, death and heart failure.\nAfter a few days have passed, though, there is little or no chance of preventing heart damage.\nAbout a third of heart attack patients show up after 12 hours.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The treatment discussed in the story is not a novel treatment nor was it portrayed as such.", "answer": 1}, {"article": "At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\n\u201cI keep waiting for the day when I have shortness of breath,\u201d he said.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\nHe has life insurance and long-term care insurance.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research is certifiably novel, although other studies have looked for genetic determinants.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes plain that the surgery is commonly done and makes no claim for its novelty. ", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\nAnd microRNAs offer a promising way to assess concussions in adults as well as children, says Bhomia, whose research involves a range of \"biomarkers\" for traumatic brain injury.\nBut up to 25 percent of young patients \"go on to have these prolonged headaches, fatigue, nausea, and those symptoms can last sometimes one to four months,\" Hicks says.\nAnd, right now, there's no way to know which kids are going to have long-term problems, he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A spit test to predict the duration of concussion symptoms would indeed be new. Also, the description of the background of the independent source in the story notes that he is also working on using microRNA tests to better understand traumatic brain injury, so readers and listeners are told that other researchers are studying similar approaches.", "answer": 1}, {"article": "\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\nUnfortunately, the drug ended up severely imbalancing his electrolytes, which can lead to dehydration, headaches, vision and cardiac problems, muscle contractions and, in extreme cases, seizures.\nIf, for example, someone decides to go on medication \u2014 be it Adderall, albuterol or piracetam \u2014 the patient must understand that there is a risk for high blood pressure and heart problems.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\n\u201cWe don\u2019t use it at all and never have.\u201d\n\nAs for newer nootropic drugs, there are unknown risks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There story gives perspective, mentioning that piracetam has been around for decades, though newer formulations are on the market, and that companies have recently begun marketing \u201cstacks\u201d with multiple supplements.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on an active debate, rather than on a new technique, technology, or drug. There are no claims to novelty, so we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "For more information about NIH and its programs, visit http://www.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nAbout the National Heart, Lung, and Blood Institute (NHLBI): NHLBI, a part of the National Institutes of Health (NIH), plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim novelty. Instead, it makes it clear that the latest results reinforce earlier findings about blood pressure management and stresses that the latest results are \u201creporting additional details about a widely-publicized study.\u201d", "answer": 1}, {"article": "Depression rates in patients taking ketamine remained low.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\n\"The approach we used here could be applied to any number of other conditions, and may reveal new and important uses for thousands of already approved drugs, without large investments in additional clinical trials,\" Makunts said.\n\"While most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite -- lack of a symptom,\" Cohen said.\nAfter the diclofenac finding, Abagyan and team went back and looked at ketamine patients who did not also take NSAIDs and compared them to patients who took any other combination of drugs for pain except NSAIDs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers often to this study being the largest of its kind and the first \u201clarge-scale\u201d study of ketamine for depression. The second sentence might lead some people to believe that this analysis is a large clinical trial \u2014 which it is not.\nThe research is novel only in its approach to claiming a benefit where there is no clear-cut relationship.\nKetamine has been tested in several small studies and research is on-going.\nThe release establishes some novelty with this statement: \u201cWhile most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite \u2014 lack of a symptom.\u201d But the fact remains, this is questionable science.", "answer": 0}, {"article": "But some cancer organizations reject the panel's advice.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nIn comparison, there was an 18 percent reduction in the rate of death in the non-screened group versus the control group, the study found.\n\"Our observed 10 percent reduction in death from breast cancer is much lower than previously thought,\" Kalager said.\nThe analysis, published in the Sept. 23 issue of the New England Journal of Medicine, raises new questions about the benefits versus risks of screening mammography and is already reigniting tensions over its frequency of use in the United States.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that, far from novel, mammography is a frequently used screening procedure that is coming under new scrutiny because of mounting evidence that it does not produce the benefits early research showed.", "answer": 1}, {"article": "\u201cThe No.\n\u201cIt would be incorporated into these dreams where I was tied up, like in the movie \u2018Alien.\u2019 It was more difficult to sleep with that thing on than to just get through the night with the apnea.\u201d\n\nMr. Bleck got rid of the machine after he discovered Provent.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nUnlike C.P.A.P., Provent is not covered by Medicare and most major insurers, though some doctors say they expect that will change in the near future.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins by contrasting this new treatment with the existing treatment. It says \u201cFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing. C.P.A.P. reduces and in some cases completely prevents episodes of apnea. But the mask is like something from a bad science fiction movie: big, bulky and obtrusive. Many patients simply refuse to wear it or rip it off while asleep. Studies show that about half of all people prescribed C.P.A.P. machines stop using them in one to three weeks.\u201d The story makes the claim that the Provent patch is \u201cfar less intrusive than the traditional C.P.A.P. machine.\u201d The claim of novelty is not backed up by the evidence presented in the story or by any published clinical trial.\u00a0 As we noted above about one out of every six people using the Provent in the study stopped using it after 3 months.", "answer": 0}]